<SEC-DOCUMENT>0001104659-25-058593.txt : 20250611
<SEC-HEADER>0001104659-25-058593.hdr.sgml : 20250611
<ACCEPTANCE-DATETIME>20250611172959
ACCESSION NUMBER:		0001104659-25-058593
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250610
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250611
DATE AS OF CHANGE:		20250611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEGA HEALTHCARE INVESTORS INC
		CENTRAL INDEX KEY:			0000888491
		STANDARD INDUSTRIAL CLASSIFICATION:	REAL ESTATE INVESTMENT TRUSTS [6798]
		ORGANIZATION NAME:           	05 Real Estate & Construction
		EIN:				383041398
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11316
		FILM NUMBER:		251040996

	BUSINESS ADDRESS:	
		STREET 1:		303 INTERNATIONAL CIRCLE,
		STREET 2:		SUITE 200
		CITY:			HUNT VALLEY
		STATE:			MD
		ZIP:			21030
		BUSINESS PHONE:		410-427-1700

	MAIL ADDRESS:	
		STREET 1:		303 INTERNATIONAL CIRCLE,
		STREET 2:		SUITE 200
		CITY:			HUNT VALLEY
		STATE:			MD
		ZIP:			21030
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2517623d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ohi="http://omegahealthcare.com/20250610">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_ohi_omegahealthcare.com_20250610 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20250610_20250610 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0000888491 -->
<!-- Field: Set; Name: xdx; ID: xdx_071_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\EntityInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000004" name="dei:EntityCentralIndexKey">0000888491</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ohi-20250610.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-06-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000888491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-10</xbrli:startDate>
        <xbrli:endDate>2025-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 2in"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_906_edei--DocumentType_c20250610__20250610_zbP7W3ycPHUk"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 2in"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_90A_edei--DocumentPeriodEndDate_c20250610__20250610_zLJ9dpuV4nl3"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">June 10, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityRegistrantName_c20250610__20250610_zy7xAqmYGUm2"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000012" name="dei:EntityRegistrantName">OMEGA HEALTHCARE INVESTORS, INC.</ix:nonNumeric></span></b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 33%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20250610__20250610_zRcXqap1mmUg"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Maryland</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b><span id="xdx_901_edei--EntityFileNumber_c20250610__20250610_zktkjaT9w7m9"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000014" name="dei:EntityFileNumber">1-11316</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20250610__20250610_z6G5PKiPQZJl"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000015" name="dei:EntityTaxIdentificationNumber">38-3041398</ix:nonNumeric></span></b></span></td></tr>


<tr style="vertical-align: top">
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">(State or other jurisdiction of<br/>
 incorporation)</span></td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20250610__20250610_zDcTRkvpOEU5"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000016" name="dei:EntityAddressAddressLine1">303 International Circle</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine2_c20250610__20250610_zFxALh1vaY3c"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20250610__20250610_zMs4XLiSeZMe"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000018" name="dei:EntityAddressCityOrTown">Hunt Valley</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20250610__20250610_zZGQpYdn4WN1"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20250610__20250610_zGNZw6bW2JBa"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000020" name="dei:EntityAddressPostalZipCode">21030</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
/ Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90E_edei--CityAreaCode_c20250610__20250610_zSTHS2HVm62g"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000021" name="dei:CityAreaCode">410</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20250610__20250610_zqlhcseJCWrl"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000022" name="dei:LocalPhoneNumber">427-1700</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90C_edei--WrittenCommunications_c20250610__20250610_zN6jXbVPaSIc"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_906_edei--SolicitingMaterial_c20250610__20250610_zUfDOQtiq517"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20250610__20250610_zSOCrjzfijd2"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20250610__20250610_zKP2zNAAWyRc"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities registered pursuant to Section
12(b) of the Securities Exchange Act of 1934:</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border: black 1pt solid; border-image: none; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
<tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20250610__20250610_zYHHfnUxdIyd"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000027" name="dei:Security12bTitle">Common Stock, $.10 par value</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20250610__20250610_zVH7nxrGtH0f"><ix:nonNumeric contextRef="AsOf2025-06-10" id="Fact000028" name="dei:TradingSymbol">OHI</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt"><span style="font-size: 10pt"><span id="xdx_902_edei--SecurityExchangeName_c20250610__20250610_zxF2gZ4WqGLf"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">New York Stock Exchange</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company&#160;<span style="font-family: Wingdings"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20250610__20250610_zPxNBk7S1bT3"><ix:nonNumeric contextRef="AsOf2025-06-10" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 10, 2025, Omega Healthcare Investors, Inc.
(&#8220;Omega&#8221;) issued a press release announcing the pricing of an underwritten public offering (the &#8220;Offering&#8221;) of
$600,000,000 aggregate principal amount of 5.200% Senior Notes due 2030. The press release announcing the pricing of the Offering is filed
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Also on June 10, 2025, Omega entered into an underwriting
agreement (the &#8220;Underwriting Agreement&#8221;) with the representatives of the several underwriters named therein relating to the
Offering. The net proceeds from the Offering, after deducting the underwriting discount but before deducting estimated Offering expenses
payable by Omega, are expected to be approximately $591,108,000, which Omega intends to use for general corporate purposes, which may
include, among other things, repayment of existing indebtedness and future acquisition or investment opportunities in healthcare-related
real estate properties and to pay certain fees and expenses related to the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The foregoing is a summary
description of certain terms of the Underwriting Agreement and is qualified in its entirety by reference to the Underwriting Agreement,
which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">(d) Exhibits. The following exhibits
are being filed herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 10%"><span style="font-size: 10pt"><b>No.</b></span></td>
    <td style="padding: 0.25pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 88%; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top"><a href="tm2517623d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">1.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; text-align: left; vertical-align: top"><a href="tm2517623d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Underwriting Agreement, dated June 10, 2025, by and among Omega and the representatives of the underwriters named therein</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top"><a href="tm2517623d1_ex99-1.htm"><span style="font-size: 10pt">99.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top"><a href="tm2517623d1_ex99-1.htm"><span style="font-size: 10pt">Press Release, dated June 10, 2025</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529"><b>OMEGA HEALTHCARE INVESTORS, INC.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="width: 50%">&#160;</td>
<td style="width: 5%">&#160;</td>
<td style="width: 45%">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Dated: June <span>11</span>, 2025</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">By:</span></td>
<td style="border-bottom: black 1pt solid">/s/ Robert O. Stephenson</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>Name:</td>
<td style="border-bottom: Black 1pt solid">Robert O. Stephenson</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>Title:</td>
<td style="border-bottom: Black 1pt solid">Chief Financial Officer</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUq3JPAxqYgsQiJ63XKKJd2R2c3yk/rLViUaBobh3nOvECOxppUukeG8yDM4YlWXyiHkeENGc0XvSDfbBPzN8a6tY2Vc//7AlDyDnonHUl680FsbbbFIIIwn02giZxDKJJrDYSeCTk/J3HSBxmlVgjIFHJhq1ugUt0PCUb3JUNX2VSdkq8kkEI3DQf6ADCMJe2rUi/hhIctSEYz6CcSa6Vl71/Lt0HQkLEusfJ0d6P8GXwZJSow= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2517623d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font-size: 10pt; margin: 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 1.1</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: right"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>OMEGA HEALTHCARE
INVESTORS, INC.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$600,000,000<BR>
5.200% Senior Notes due 2030</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>UNDERWRITING
AGREEMENT</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt; text-decoration: none">June
10, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wells Fargo Securities, LLC<BR>
550 South Tryon Street, 5<SUP>th</SUP> Floor<BR>
Charlotte, North Carolina 28202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities, Inc.<BR>
One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Credit Agricole Securities (USA) Inc.<BR>
1301 Avenue of the Americas<BR>
New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. Morgan Securities LLC<BR>
383 Madison Avenue, 6<SUP>th</SUP> Floor<BR>
New York, New York 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representatives of the several<BR>
Underwriters listed in <U>Schedule 1</U> hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Omega Healthcare Investors, Inc., a Maryland corporation
(the &ldquo;<U>Company</U>&rdquo;), and the Company&rsquo;s subsidiary, OHI Healthcare Properties Limited Partnership, a Delaware limited
partnership (the &ldquo;<U>Subsidiary Guarantor</U>&rdquo;), hereby confirm their agreement with you, as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>The Securities</U>. Subject to
the terms and conditions herein contained, the Company proposes to issue and sell to the several Underwriters named in <U>Schedule 1</U>
(the &ldquo;<U>Underwriters</U>&rdquo;) $600,000,000 aggregate principal amount of its 5.200% Senior Notes due 2030 (the &ldquo;<U>Notes</U>&rdquo;).
The Notes will be unconditionally guaranteed (the &ldquo;<U>Guarantee</U>&rdquo;) on a senior, unsecured basis by the Subsidiary Guarantor.
The Notes and the Guarantee are collectively referred to herein as the &ldquo;<U>Securities</U>.&rdquo; The Notes are to be issued pursuant
to an indenture (the &ldquo;<U>Base Indenture</U>&rdquo;) to be dated as of June 20, 2025 by and among the Company, the Subsidiary Guarantor
and U.S. Bank Trust Company, National Association, as Trustee (the &ldquo;<U>Trustee</U>&rdquo;), as supplemented by the First Supplemental
Indenture, to be dated as of June 20, 2025 (the &ldquo;<U>First Supplemental Indenture</U>&rdquo;, and together with the Base Indenture,
the &ldquo;<U>Indenture</U>&rdquo;). Each of Wells Fargo Securities, LLC, BofA Securities, Inc., Credit Agricole Securities (USA) Inc.
and J.P. Morgan Securities, LLC has agreed to act as the representatives of the several Underwriters (the &ldquo;<U>Representatives</U>&rdquo;)
in connection with the offering and sale of the Securities. The Company and the Subsidiary Guarantor hereby confirm their agreement with
the several Underwriters concerning the purchase and sale of the Securities, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Registration
Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) under
the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &ldquo;<U>Act</U>&rdquo;),
a registration statement on Form S-3 (File No. 333-282376), including a prospectus, relating to the Securities. Such registration statement,
as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Act
to be part of the registration statement at the time of its effectiveness (&ldquo;<U>Rule 430 Information</U>&rdquo;), is referred to
herein as the &ldquo;<U>Registration Statement</U>&rdquo;; and as used herein, the term &ldquo;<U>Preliminary Prospectus</U>&rdquo; means
each prospectus included in such registration statement (and any amendments thereto) before it became effective, any prospectus filed
with the Commission pursuant to Rule 424(a) or 424(b) under the Act and the prospectus included in the Registration Statement at the time
of its effectiveness that omits Rule 430 Information, and the term &ldquo;<U>Prospectus</U>&rdquo; means the prospectus in the form first
used (or made available to the Underwriters upon request of purchasers pursuant to Rule 173 under the Act) in connection with confirmation
of sales of the Securities. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Act (the
 &ldquo;<U>Rule 462 Registration Statement</U>&rdquo;), then any reference herein to the term &ldquo;<U>Registration Statement</U>&rdquo;
shall be deemed to include such Rule 462 Registration Statement. Any reference in this agreement (&ldquo;<U>Agreement</U>&rdquo;) to the
Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated
by reference therein pursuant to Item 12 of Form S-3 under the Act, as of the effective date of the Registration Statement or the date
of such Preliminary Prospectus or the Prospectus, as the case may be and any reference to &ldquo;<U>amend</U>&rdquo;, &ldquo;<U>amendment</U>&rdquo;
or &ldquo;<U>supplement</U>&rdquo; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed
to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations
of the Commission thereunder (collectively, the &ldquo;<U>Exchange Act</U>&rdquo;) that are deemed to be incorporated by reference therein.
Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">At or prior to 3:50 p.m., New York City time,
on June 10, 2025, the time when sales of the Securities were first made (the &ldquo;<U>Time of Execution</U>&rdquo;), the Company
had prepared the following information (collectively, the &ldquo;<U>Pricing Disclosure Package</U>&rdquo;): a Preliminary Prospectus dated
June 10, 2025 and each &ldquo;<U>free writing prospectus</U>&rdquo; (as defined pursuant to Rule 405 under the Act) listed on Annex
A hereto as constituting part of the Pricing Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Representations and Warranties</U>.
As of the Time of Execution and at the Closing Date, each of the Company and the Subsidiary Guarantor, jointly and severally, represents
and warrants to and agrees with each of the Underwriters as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary
Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Act and
did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading. At the Time of Execution,
the Pricing Disclosure Package did not, and on the Closing Date, will not contain any untrue statement of a material fact or omit to state
any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U>, <U>however</U>, that each of the Company and the Subsidiary Guarantor makes no representation or warranty as to the information
contained in or omitted from the Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, in reliance upon and in conformity
with information furnished in writing to the Company by or on behalf of the Underwriters through the Representatives specifically for
inclusion therein. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no
statement of material fact included in the Pricing Disclosure Package that is required to be included in the Prospectus has been omitted
therefrom. The Company has not distributed or referred to and will not distribute or refer to any written communications (as defined in
Rule 405 of the Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the
Company or its agents and representatives (other than a communication referred to in clauses (i), (ii) and (iii) below) an &ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo;) other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Act
or Rule 134 under the Act, (ii) the Preliminary Prospectus, (iii) the Prospectus, (iv) the documents listed on Annex A hereto as constituting
part of the Pricing Disclosure Package and (v) any recorded electronic road show, made available to investors. Each such Issuer Free Writing
Prospectus complies in all material respects with the Act, has been or will be (within the time period specified in Rule 433 under the
Act) filed in accordance with the Act (to the extent required thereby) and, when taken together with the Preliminary Prospectus accompanying
or filed prior to the first use of such Issuer Free Writing Prospectus, did not at the Time of Execution, and at the Closing Date will
not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <U>provided</U>, <U>however</U>, that each of the Company
and the Subsidiary Guarantor makes no representation or warranty as to the information contained in or omitted from each such Issuer Free
Writing Prospectus, in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of the Underwriters
through the Representatives specifically for inclusion therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Registration Statement is an &ldquo;automatic shelf registration statement&rdquo; as defined under Rule 405 of the Act that
has been filed with the Commission not earlier than three years prior to the date hereof; and no notice of objection of the Commission
to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act has been received
by the Company. No order suspending the effectiveness of the Registration Statement has been issued by the Commission and no proceeding
for that purpose or pursuant to Section 8A of the Act against the Company or related to the offering of the Securities has been initiated
or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and
any amendment thereto, the Registration Statement complied and will comply in all material respects with the Act and the Trust Indenture
Act of 1939, as amended, and the rules and regulations of the Commission thereunder (collectively, the &ldquo;<U>Trust Indenture Act</U>&rdquo;),
and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto
and as of the Closing Date, the Prospectus will not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to (i) that part of the Registration
Statement that constitutes the Statement of Eligibility and Qualification (Form T-1) of the Trustee under the Trust Indenture Act or (ii)
any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company
in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any
amendment or supplement thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Registration Statement,
the Prospectus and the Pricing Disclosure Package (an &ldquo;<U>Incorporated Document</U>&rdquo;) complied when such documents were filed
with the Commission, or will comply when so filed, in all material respects with the Exchange Act and the applicable rules and regulations
thereunder. None of the Incorporated Documents, when filed with the Commission, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement,
the Prospectus or the Pricing Disclosure Package, when such documents become effective or are filed with the Commission, as the case may
be, will conform in all material respects to the requirements of the Act or the Exchange Act, as applicable, and will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All of the issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued and are fully
paid and non-assessable and were not issued in violation of any preemptive right, resale right, right of first refusal or similar right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Maryland,
with full corporate power and authority to acquire, own, lease and operate its properties, and to lease the same to others, and to conduct
its business as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, to execute and deliver this
Agreement and to issue, sell and deliver the Notes as contemplated herein. The Company is in compliance in all respects with the laws,
orders, rules, regulations and directives issued or administered by such jurisdictions, except where the failure to be in compliance would
not, individually or in the aggregate, either (i) have a material adverse effect on the business, properties, financial condition, results
of operation or prospects of the Company and the Subsidiaries (each, a &ldquo;<U>Subsidiary</U>&rdquo; and collectively, the &ldquo;<U>Subsidiaries</U>&rdquo;
as defined under the Act) taken as a whole or (ii) prevent consummation of the transactions contemplated hereby (the occurrence of such
effect or such prevention described in the foregoing clauses (i) and (ii) being herein referred to as a &ldquo;<U>Material Adverse Effect</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company is duly qualified to do business as a foreign entity and is in good standing in each jurisdiction where the ownership
or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified and
in good standing would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>On the Closing Date, the Subsidiary Guarantor will issue its Guarantee of the Notes; as of March 31, 2025, the Company owned, directly
or indirectly, approximately 97% of the issued and outstanding equity interests of the Subsidiary Guarantor. The Company does not own,
directly or indirectly, any shares of stock or any other equity or long-term debt securities of any corporation or have any equity interest
in any firm, partnership, joint venture, association or other entity other than the equity interests of the Subsidiaries, or as would
not be material to the Company and the Subsidiaries on a consolidated basis. Complete and correct copies of the articles of incorporation
and the bylaws of the Company and all amendments thereto have been delivered to you, and no changes therein or to the articles of incorporation
and the bylaws (or other organizational documents) of the Subsidiary Guarantor will be made from and including the date hereof through
and including the Closing Date. Each Subsidiary of the Company has been duly formed and is validly existing as a corporation, limited
liability company, limited partnership or trust in good standing under the laws of the jurisdiction of its formation, with full organizational
power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, except where the failure to be so formed and existing or to have such organizational power
and authority would not, individually or in the aggregate, have a Material Adverse Effect. Each Subsidiary is duly qualified to do business
as a foreign corporation, limited liability company, limited partnership or trust and is in good standing in each jurisdiction where the
ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified
and in good standing would not, individually or in the aggregate, have a Material Adverse Effect. Each Subsidiary is in compliance in
all respects with the laws, orders, rules, regulations and directives issued or administered by such jurisdictions, except where the failure
to be in compliance would not, individually or in the aggregate, have a Material Adverse Effect. All of the outstanding shares of equity
interests of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and non-assessable and, except for
the Subsidiary Guarantor, OHI Asset II (CA), LLC and OHI Healthcare Properties Limited Partnership, L.P., which are owned, directly or
indirectly, by the Subsidiary Guarantor, are subject to no security interest, other material encumbrance or adverse claims. Except with
respect to the Subsidiary Guarantor, no options, warrants or other rights to purchase, agreements or other obligations to issue or other
rights to convert any obligation into shares of capital stock or ownership interests in the Subsidiaries are outstanding. The Company
has no &ldquo;significant subsidiary,&rdquo; as that term is defined in Rule 1-02(w) of Regulation S-X under the Act, other than (i) the
Subsidiary Guarantor and (ii) those listed in Exhibit 21.1 to the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended
December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company has all requisite corporate power and authority to execute, deliver and perform each of its obligations under the Notes.
The Notes, when issued, will be in the form contemplated by the Indenture. The Notes have been duly and validly authorized by the Company
and, when executed by the Company and authenticated by the Trustee in accordance with the provisions of the Indenture, and when delivered
to and paid for by the Underwriters in accordance with the terms of this Agreement, will constitute valid and legally binding obligations
of the Company, entitled to the benefits of the Indenture, and enforceable against the Company in accordance with their terms, except
that the enforcement thereof may be subject to (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other
similar laws now or hereafter in effect relating to creditors&rsquo; rights generally and (ii) general principles of equity and the discr<FONT STYLE="color: black">etion
of the court before which any proceeding therefor may be brought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subsidiary Guarantor has all requisite organizational power and authority to execute, deliver and perform each of its obligations
under the Guarantee. The Guarantee, when issued, will be in the form contemplated by the Indenture. The Guarantee has been duly and validly
authorized by the Subsidiary Guarantor and, when the Guarantee is executed by the Subsidiary Guarantor and the Notes are authenticated
by the Trustee in accordance with the provisions of the Indenture, will have been duly executed, issued and delivered and will constitute
a valid and legally binding obligation of the Subsidiary Guarantor, entitled to the benefits of the Indenture, and enforceable against
the Subsidiary Guarantor in accordance with its terms, subject to (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium
or other similar laws now or hereafter in effect relating to creditors&rsquo; rights generally and (ii) general principles of equity and
the discretion of the court before which any proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company and the Subsidiary Guarantor have all requisite corporate or organizational power and authority to execute, deliver
and perform its obligations under the Indenture. The Indenture has been duly qualified under the Trust Indenture Act, and the Indenture
meets the requirements for qualification under the Trust Indenture Act and upon effectiveness of the Registration Statement was or will
have been duly qualified under the Trust Indenture Act. The Indenture has been duly and validly authorized by the Company and the Subsidiary
Guarantor and, when executed and delivered by the Company and the Subsidiary Guarantor (assuming the due authorization, execution and
delivery by the Trustee), will constitute a valid and legally binding agreement of the Company and the Subsidiary Guarantor, enforceable
against the Company and the Subsidiary Guarantor in accordance with its terms, except that the enforcement thereof may be subject to (i)
bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other similar laws now or hereafter in effect relating to
creditors&rsquo; rights generally and (ii) general principles of equity and the discretion of the court before which any proceeding therefor
may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company and the Subsidiary Guarantor have all requisite corporate or organizational power and authority to execute, deliver
and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. This Agreement and the consummation
by the Company and the Subsidiary Guarantor of the transactions contemplated hereby have been duly authorized by the Company and the Subsidiary
Guarantor. This Agreement has been duly and validly executed and delivered by the Company and the Subsidiary Guarantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither the Company nor any of the Subsidiaries is in breach or violation of or in default under (nor has any event occurred which
with notice, lapse of time or both would result in any breach or violation of, constitute a default under or give the holder of any indebtedness
(or a person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a part of such
indebtedness under) its (i) respective charter or bylaws (or other formation documents), (ii) any indenture, mortgage, deed of trust,
bank loan or credit agreement or other evidence of indebtedness, or any license, lease, contract or other agreement or instrument to which
the Company or any of the Subsidiaries is a party or by which any of them or any of their respective properties may be bound or affected
(including, without limitation, the Indenture) or (iii) any federal, state, local or foreign law, regulation or rule, including, without
limitation, the rules and regulations of the New York Stock Exchange (the &ldquo;<U>NYSE</U>&rdquo;), or any decree, judgment or order
applicable to the Company or any of the Subsidiaries or any of their respective properties, except in the case of clauses (ii) and (iii)
above, for such breaches, violations or defaults as would not, individually or in the aggregate, have a Material Adverse Effect. The execution,
delivery and performance of this Agreement, the issuance and sale of the Securities and the consummation of the transactions contemplated
hereby will neither (A) conflict with, result in any breach or violation of or constitute a default under (nor constitute any event which
with notice, lapse of time or both would result in any breach or violation of or constitute a default under or give the holder of any
indebtedness (or a person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or
a part of such indebtedness under) (1) the charter or bylaws (or other formation documents) of the Company or any of the Subsidiaries,
(2) any indenture, mortgage, deed of trust, bank loan or credit agreement or other evidence of indebtedness, or any license, lease, contract
or other agreement or instrument to which the Company or any of the Subsidiaries is a party or by which any of them or any of their respective
properties may be bound or affected (including, without limitation, the Indenture), or (3) any federal, state or local law, regulation
or rule, including the rules and regulations of the NYSE, or any decree, judgment or order applicable to the Company or any of the Subsidiaries,
except in the case of clause (2) above, for such breaches, violations or defaults as would not, individually or in the aggregate, have
a Material Adverse Effect, nor (B) result in the creation or imposition of any lien, charge, claim or encumbrance upon any of the properties
(real and personal (including, without limitation, mortgage loans and unsecured loans)) described in the Registration Statement, the Pricing
Disclosure Package or the Prospectus as being owned or leased by the Company or any of the Subsidiaries (collectively, the &ldquo;<U>Properties</U>&rdquo;,
and each individually, a &ldquo;<U>Property</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No approval, authorization, consent or order of or filing with any federal, state, local or foreign governmental or regulatory
commission, board, body, authority or agency, or of or with the NYSE, or approval of the stockholders of the Company, is required in connection
with the issuance and sale of the Securities or the consummation by the Company or the Subsidiary Guarantor of the transactions contemplated
hereby other than which has been effected and any necessary qualification under the securities or &ldquo;Blue Sky&rdquo; laws of the various
jurisdictions in which the Securities are being offered by the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as expressly set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no person has the
right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Securities, whether
as a result of the sale of the Securities as contemplated thereby or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each of the Company and the Subsidiaries (and to the Company&rsquo;s knowledge, each operator, lessee or sublessee of any Property
(as defined below) or portion thereof) (i) has all necessary licenses, authorizations, consents and approvals, (ii) has made all necessary
filings required under any federal, state, local or foreign law, regulation or rule, and (iii) has obtained all necessary licenses, authorizations,
consents and approvals from other persons, in order to acquire and own, lease or sublease, lease to others and conduct its respective
business as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except in the case of clauses
(i), (ii) and (iii) above, where the failure to have such items, make such filings or obtain such items would not, individually or in
the aggregate, have a Material Adverse Effect. Neither the Company nor any of the Subsidiaries (nor, to the knowledge of the Company or
the Subsidiary Guarantor, any such operator, lessee or sublessee) is in violation of, or in default under, or has received notice of any
proceedings relating to revocation or modification of, any such license, authorization, consent or approval or any federal, state, local
or foreign law, regulation or rule or any decree, order or judgment applicable to the Company or any of the Subsidiaries, except where
such violation, default, revocation or modification would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All legal or governmental proceedings, affiliate transactions, off-balance sheet transactions (including, without limitation, transactions
related to, and the existence of, &ldquo;variable interest entities&rdquo; within the meaning of Accounting Standards Codification 810,
<I>Consolidation</I>), contracts, licenses, agreements, leases or documents required to be described in the Registration Statement or
to be filed as an exhibit to the Registration Statement or any incorporated document have been so described or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no actions, suits,
claims, investigations or proceedings pending or, to the knowledge of the Company or the Subsidiary Guarantor, threatened or contemplated
to which the Company or any of the Subsidiaries, or any of their respective directors or officers (or, to the Company&rsquo;s knowledge,
any person from whom the Company or any Subsidiary acquired any of the Properties (each, a &ldquo;<U>seller</U>&rdquo;), or any lessee,
sublessee or operator of any Property or any portion thereof) is or would be a party, or of which any of the respective properties or
assets of the Company and the Subsidiaries, or any Property, is or would be subject at law or in equity, before or by any federal, state,
local or foreign governmental or regulatory commission, board, body, authority or agency, except any such action, suit, claim, investigation
or proceeding which would not result in a judgment, decree or order having, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Ernst &amp; Young LLP, whose report on the consolidated financial statements of the Company and the Subsidiaries is incorporated
by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, are independent public accountants
as required by the Act and by Rule 3600T of the Public Company Accounting Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The audited consolidated financial statements of the Company and the Subsidiaries included or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, together with the related notes, present fairly the consolidated
financial position of the Company and the Subsidiaries as of the dates indicated and the consolidated results of operations and cash flows
of the Company and the Subsidiaries for the periods specified and have been prepared in compliance with the applicable requirements of
the Act and the Exchange Act and in conformity with generally accepted accounting principles in the United States (&ldquo;GAAP&rdquo;)
applied on a consistent basis during the periods involved (except, in the case of unaudited financial statements, for normal year-end
adjustments and the absence of notes). The other financial and statistical data set forth or incorporated by reference in the Registration
Statement, the Pricing Disclosure Package and the Prospectus are fairly presented in all material respects and prepared on a basis consistent
with the financial statements and books and records of the Company. Any pro forma financial statements and related notes thereto included
in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus have been prepared in accordance with the requirements
of the Act and the Exchange Act relating to such pro forma financial statements (as if such pro forma financial statements were included
in a registration statement) and the assumptions underlying the adjustments set forth in such pro forma financial information are reasonable
and are set forth in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus. There are no financial statements
(historical or pro forma) that are required to be included or incorporated by reference in the Registration Statement, the Pricing Disclosure
Package or the Prospectus (including, without limitation, as required by Rules 3-12 or 3-05 or Article 11 of Regulation S-X under the
Act to the extent applicable) that are not included as required. The Company and the Subsidiaries do not have any material liabilities
or obligations, direct or contingent (including any off-balance sheet obligations or any &ldquo;variable interest entities&rdquo; within
the meaning of Accounting Standards Codification 810, <I>Consolidation</I>), not disclosed in the Registration Statement, the Pricing
Disclosure Package or the Prospectus. The interactive data in eXtensible Business Reporting Language included or incorporated by reference
in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly present the information called for in
all material respects and have been prepared in accordance with the Commission&rsquo;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subsequent to the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, there has not been (i) any material adverse change, or any development which could have a reasonable possibility of
giving rise to a prospective material adverse change, in the business, properties, management, financial condition or results of operations
of the Company and the Subsidiaries taken as a whole, (ii) any transaction which is material to the Company and the Subsidiaries taken
as a whole, (iii) any obligation, direct or contingent (including any off-balance sheet obligations), incurred by the Company or any Subsidiary,
which is material to the Company and the Subsidiaries taken as a whole, (iv) any material adverse change in the capital stock (except
as the result of the exercise, vesting, or forfeiture of rights or awards held by directors and employees under the Company&rsquo;s stock
incentive plans described in the Registration Statement, the Pricing Disclosure Package or the Prospectus or issuances under the Company&rsquo;s
dividend reinvestment and common stock purchase plan, or upon the redemption of outstanding units of the Subsidiary Guarantor in accordance
with the terms of its partnership agreement) or any Subsidiary or (v) any dividend or distribution of any kind declared, paid or made
on the capital stock of the Company or any Subsidiary except for regular quarterly dividends of the Company, corresponding distributions
by the Subsidiary Guarantor, distributions on preferred units of the Subsidiary REITs in accordance with the terms of their respective
organizational documents, dividends and distributions of Subsidiaries payable to the Company or Subsidiaries, or as disclosed in the Registration
Statement, the Pricing Disclosure Package or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither the Company nor any Subsidiary is and, after giving effect to the offering and sale of the Securities and the consummation
of the transactions contemplated hereby, neither of them will be an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo;
by an &ldquo;investment company,&rdquo; as such terms are defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>None of the Company, the Subsidiaries or any agent acting on their behalf, other than the Underwriters (as to which the Company
does not represent), has taken or will take any action that would cause this Agreement or the sale of the Notes to violate Regulation
T, U or X of the Board of Governors of the Federal Reserve System, in each case as in effect, or as the same may hereafter be in effect,
on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company, and each of the Subsidiaries, has insurable title, and, in the case of real property, in fee simple, to the Properties,
free and clear of all liens, claims, mortgages, deeds of trust, restrictions, security interests and other encumbrances or defects (&ldquo;<U>Property
Encumbrances</U>&rdquo;), except for (x) the leasehold interests of lessees in the Properties of the Company and the Subsidiaries held
under lease (the &ldquo;<U>Leases</U>&rdquo;) and (y) any other Property Encumbrances that would not, individually or in the aggregate,
have a Material Adverse Effect. All Property Encumbrances on or affecting the Properties which are required to be disclosed in the Registration
Statement, the Pricing Disclosure Package and Prospectus are disclosed therein as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each of the Leases pertaining to the Properties has been duly authorized by the Company or a Subsidiary, as applicable, and is
a valid, subsisting and enforceable agreement of the Company or such Subsidiary, as applicable, and, to the knowledge of the Company,
each other party thereto, enforceable in accordance with its terms, except where the failure of such Lease to be duly authorized, or a
valid, subsisting and enforceable agreement of the Company or such Subsidiary, as applicable, would not, individually or in the aggregate,
have a Material Adverse Effect, and except as such enforceability may be limited by bankruptcy, insolvency, reorganization or other similar
laws affecting creditors&rsquo; rights generally or general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>To the knowledge of the Company or the Subsidiary Guarantor, except as disclosed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, no lessee of any portion of any of the Properties is in default under its respective lease, and there is no
event which, with notice, lapse of time or both, would constitute a default under any such lease, except such defaults that would not,
individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>To the knowledge of the Company or the Subsidiary Guarantor, except as disclosed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, no borrower of a mortgage loan from the Company is in default under its respective mortgage loan, and there
is no event which, with notice, lapse of time or both, would constitute a default under any such mortgage loan, except such defaults that
would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither the Company nor any of the Subsidiaries is engaged in any unfair labor practice, except as would not, individually or in
the aggregate, have a Material Adverse Effect. There has been no violation of any federal, state or local law relating to discrimination
in the hiring, promotion or pay of employees, any applicable wage or hour laws or any provision of the Employee Retirement Income Security
Act of 1974 or the rules and regulations promulgated thereunder concerning the employees of the Company or any of the Subsidiaries, except
as would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and the Subsidiaries
and their properties, assets and operations (and, to the knowledge of the Company or the Subsidiary Guarantor, each operator or lessee
of any Property or portion thereof) are in compliance with, and hold all permits, authorizations and approvals required under, Environmental
Laws (as defined below), except to the extent that failure to so comply or to hold such permits, authorizations or approvals would not,
individually or in the aggregate, have a Material Adverse Effect. There are no past, present or, to the knowledge of the Company or the
Subsidiary Guarantor, reasonably anticipated future events, conditions, circumstances, activities, practices, actions, omissions or plans
that could reasonably be expected to give rise to any material costs or liabilities to the Company or any Subsidiary under, or to interfere
with or prevent compliance by the Company or any Subsidiary with, Environmental Laws, except as would not, individually or in the aggregate,
have a Material Adverse Effect. Except as would not, individually or in the aggregate, have a Material Adverse Effect, neither the Company
nor any of the Subsidiaries, nor, to the knowledge of the Company or the Subsidiary Guarantor, any seller, lessee, sublessee or operator
of any Property or portion thereof or any previous owner thereof, (i) is the subject of any investigation, (ii) has received any notice
or claim, (iii) is a party to or affected by any pending or threatened action, suit or proceeding, (iv) is bound by any judgment, decree
or order or (v) has entered into any agreement, in each case relating to any alleged violation of any Environmental Law or any actual
or alleged release or threatened release or cleanup at any location of any Hazardous Materials (as defined below). Neither the Company
nor any of the Subsidiaries, nor, to the knowledge of the Company or the Subsidiary Guarantor, any seller, lessee, sublessee or operator
of any Property or portion thereof or any previous owner thereof, has received from any governmental authority notice of any violation,
concerning the Properties, of any municipal, state or federal law, rule or regulation or of any Environmental Law, except for such violations
as have heretofore been cured and except for such violations as would not, individually or in the aggregate, have a Material Adverse Effect.
As used herein, &ldquo;<U>Environmental Law</U>&rdquo; means any federal, state or local law, statute, ordinance, rule, regulation, order,
decree, judgment, injunction, permit, license, authorization or other binding requirement, or common law, relating to health, safety or
the protection, cleanup or restoration of the environment or natural resources, including those relating to the distribution, processing,
generation, treatment, storage, disposal, transportation, other handling or release or threatened release of Hazardous Materials, and
 &ldquo;<U>Hazardous Materials</U>&rdquo; means any material (including, without limitation, pollutants, contaminants, hazardous or toxic
substances or wastes) that is regulated by or may give rise to liability under any Environmental Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company and the Subsidiaries have (A) all licenses, certificates, permits, authorizations, approvals, franchises and other
rights from, and have made all declarations and filings with, all applicable authorities, all self-regulatory authorities and all courts
and other tribunals (each, an &ldquo;<U>Authorization</U>&rdquo;) necessary to engage in the business conducted by them in the manner
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except as would not, individually or in the
aggregate, have a Material Adverse Effect, and (B) no reason to believe that any governmental body or agency, domestic or foreign, is
considering limiting, suspending or revoking any such Authorization, except where any such limitations, suspensions or revocations would
not, individually or in the aggregate, have a Material Adverse Effect. All such Authorizations are valid and in full force and effect
and the Company and the Subsidiaries are in compliance with the terms and conditions of all such Authorizations and with the rules and
regulations of the regulatory authorities having jurisdiction with respect to such Authorizations, except for any invalidity, failure
to be in full force and effect or noncompliance with any Authorization that would not, individually or in the aggregate, have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All tax returns required to be filed by the Company or any of the Subsidiaries have been timely filed, and all taxes and other
assessments of a similar nature (whether imposed directly or through withholding and whether or not shown on a tax return) including any
interest, additions to tax or penalties applicable thereto due or claimed to be due from such entities have been timely paid, other than
those taxes being contested in good faith by appropriate proceedings and for which adequate reserves have been provided in accordance
with GAAP or the filing of tax returns or the payment of any taxes which would not, individually or in the aggregate, have a Material
Adverse Effect. There is no tax deficiency which has been or could reasonably be expected to be asserted against the Company or any Subsidiary,
except any tax deficiency which would not, individually or in the aggregate, have a Material Adverse Effect. The Company has made adequate
charges, accruals and reserves in accordance with GAAP in the applicable financial statements referred to in Section 2(s) hereof in respect
of all taxes for all periods as to which the tax liability of the Company or its Subsidiaries has not been finally determined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each of the Company and the Subsidiaries is insured by insurers of recognized financial responsibility against such losses and
risks and in such amount as the Company reasonably deems to be adequate and as are customary in the business in which they are engaged,
except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as would not, individually
or in the aggregate, have a Material Adverse Effect, all policies of insurance insuring the Company and the Subsidiaries or any of their
businesses, assets, employees, officers, directors and trustees are in full force and effect, and the Company and the Subsidiaries are
in compliance with the terms of such policies in all material respects. Except as would not, individually or in the aggregate, have a
Material Adverse Effect, there are no claims by the Company or any of the Subsidiaries under any such policy or instrument as to which
any insurance company is denying liability or defending under a reservation of rights clause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither the Company nor any of the Subsidiaries has sustained, since the date of the last audited financial statements included
or incorporated by reference in the Pricing Disclosure Package and the Prospectus, any loss or interference with its respective business
from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental
action, order or decree, except for such loss or interference as would not, individually or in the aggregate, have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company and its Subsidiaries on a consolidated basis maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s general or specific authorization, (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability
for assets, (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization and (iv)
the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect
to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company has established and maintains and evaluates &ldquo;disclosure controls and procedures&rdquo; (as such term is defined
in Rule 13a-15 and 15d-15 under the Exchange Act) and &ldquo;internal control over financial reporting&rdquo; (as such term is defined
in Rule 13a-15 and 15d-15 under the Exchange Act); such disclosure controls and procedures are designed to ensure that material information
relating to the Company, including its consolidated Subsidiaries, is made known to the Company&rsquo;s Chief Executive Officer and its
Chief Financial Officer by others within those entities, and such disclosure controls and procedures are effective to perform the functions
for which they were established; the Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have been
advised of: (i) any significant deficiencies in the design or operation of internal controls which could adversely affect the Company&rsquo;s
ability to record, process, summarize, and report financial data; and (ii) any fraud, whether or not material, that involves management
or other employees who have a role in the Company&rsquo;s internal controls. Any material weaknesses in internal controls have been identified
for the Company&rsquo;s auditors. Since the date of the most recent evaluation of such disclosure controls and procedures, there have
been no significant changes in internal controls or in other factors that could significantly affect internal controls, including any
corrective actions with regard to significant deficiencies and material weaknesses; the principal executive officers (or their equivalents)
and principal financial officers (or their equivalents) of the Company have made all certifications required by the Sarbanes-Oxley Act
of 2002 (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;) and any related rules and regulations promulgated by the Commission, and the statements
contained in any such certification are complete and correct. The Company and the Subsidiaries are in compliance in all material respects
with all applicable effective provisions of the Sarbanes-Oxley Act and the rules and regulations of the Commission and the NYSE promulgated
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Agreement, the Securities and the Indenture will conform, in all material respects to the descriptions thereof in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No person has the right to require the Company or any of its Subsidiaries to register any securities for sale under the Act by
reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Immediately after the consummation of the transactions contemplated by this Agreement, the fair value and present fair saleable
value of the assets of each of the Company and the Subsidiaries (each on a consolidated basis) will exceed the sum of its stated liabilities
and identified contingent liabilities; none of the Company or the Subsidiaries (each on a consolidated basis) is, nor will any of the
Company or the Subsidiaries (each on a consolidated basis) be, after giving effect to the execution, delivery and performance of this
Agreement, and the consummation of the transactions contemplated hereby, (a) left with unreasonably small capital with which to carry
on its business as it is proposed to be conducted, (b) unable to pay its debts (contingent or otherwise) as they mature or (c) otherwise
insolvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company is not an &ldquo;ineligible issuer&rdquo; and is a &ldquo;well-known seasoned issuer,&rdquo; in each case as defined
in Rule 405 under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No forward-looking statement (within the meaning of Section 27A of the Act and Section 21E of the Exchange Act) included or incorporated
by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without
a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company has provided you true, correct and complete copies of all documentation pertaining to any extension of credit in the
form of a personal loan made, directly or indirectly, by the Company or any Subsidiary to any director or executive officer of the Company,
or to any family member or affiliate of any director or executive officer of the Company. On or after March 31, 2025, the Company has
not, directly or indirectly, including through any Subsidiary: (i) extended credit, arranged to extend credit, or renewed any extension
of credit, in the form of a personal loan, to or for any director or executive officer of the Company, or to or for any family member
or affiliate of any director or executive officer of the Company; or (ii) made any material modification, including any renewal thereof,
to any term of any personal loan to any director or executive officer of the Company, or any family member or affiliate of any director
or executive officer, which loan was outstanding on March 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All statistical or market-related data included or incorporated by reference in the Registration Statement, the Pricing Disclosure
Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate in all material
respects, and the Company has obtained the written consent to the use of such data from such sources to the extent required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither the Company nor any of the Subsidiaries nor, to the knowledge of the Company or the Subsidiary Guarantor, any employee
or agent of the Company or any Subsidiary has made any payment of funds of the Company or any Subsidiary or received or retained any funds
in violation of any law, rule or regulation, which payment, receipt or retention of funds is of a character required to be disclosed in
the Registration Statement, the Pricing Disclosure Package, the Prospectus or any document incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Except pursuant to this Agreement, neither the Company nor any of the Subsidiaries has incurred any liability for any finder&rsquo;s
or broker&rsquo;s fee or agent&rsquo;s commission in connection with the execution and delivery of this Agreement or the consummation
of the transactions contemplated hereby or by the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(rr)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>From and including the Company&rsquo;s taxable year ended December 31, 1992, the Company was and is organized in conformity with
the requirements for, its actual methods of operation through the date hereof have permitted, and its proposed methods of operation will
permit the Company to meet the requirements for, qualification and taxation as a real estate investment trust (&ldquo;<U>REIT</U>&rdquo;)
under the Internal Revenue Code of 1986, as amended, and the Company has qualified and will so qualify, and the Company will continue
to meet such requirements and qualify as a REIT after consummation of the contemplated transactions and the application of the proceeds,
if any, from the offering of the Notes by the Company as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus. All statements in the Registration Statement, the Pricing Disclosure Package and the Prospectus regarding the Company&rsquo;s
qualification as a REIT are true, complete and correct in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(ss)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither the Company nor any of the Subsidiaries nor any of their respective directors, officers, affiliates or controlling persons
has taken, directly or indirectly, any action designed, or which has constituted or might reasonably be expected to cause or result in,
under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company to facilitate the sale
of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(tt)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Any certificate signed by any officer of the Company or the Subsidiary Guarantor and delivered to any Underwriter or to counsel
for the Underwriters shall be deemed a joint and several representation and warranty by the Company and the Subsidiary Guarantor to each
Underwriter as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(uu)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither the Company nor any of the Subsidiaries, nor any director, officer or employee of the Company or any of the Subsidiaries
nor, to the knowledge of the Company or the Subsidiary Guarantor, any agent, affiliate or other person associated with or acting on behalf
of the Company or any of the Subsidiaries has: (i) used any corporate funds of the Company or any of the Subsidiaries for any unlawful
contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act on behalf of the
Company or any of the Subsidiaries in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or
benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public
international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party
or party official or candidate for political office; (iii) taken an act on behalf of the Company or any of the Subsidiaries in violation
of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention
on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act
2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken
an act on behalf of the Company or any of the Subsidiaries in furtherance of any unlawful bribe or other unlawful benefit, including,
without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and
the Subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce, policies and procedures designed to
promote and ensure compliance with all applicable anti-bribery and anticorruption laws appropriate for the nature of the Company&rsquo;s
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(vv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
the applicable money laundering statutes of all jurisdictions where the Company or any of the Subsidiaries conducts business, the rules
and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the &ldquo;<U>Anti-Money Laundering Laws</U>&rdquo;), and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of the Subsidiaries with respect to the Anti-Money
Laundering Laws is pending or, to the knowledge of the Company or the Subsidiary Guarantor, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(ww)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither the Company nor any of the Subsidiaries, the Company&rsquo;s and the Subsidiaries&rsquo; directors, officers or employees,
nor, to the knowledge of the Company or the Subsidiary Guarantor, any agent, affiliate or other person associated with or acting on behalf
of the Company or any of the Subsidiaries is currently the subject or the target of any sanctions or trade embargoes imposed, administered
or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the
Treasury or the U.S. Department of State and including, without limitation, the designation as a &ldquo;specially designated national&rdquo;
or &ldquo;blocked person&rdquo;), the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury or other relevant
sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;), nor is the Company or any of the Subsidiaries located, organized or
resident in a country or territory that is the subject or target of country- or territory-wide Sanctions, including, without limitation,
the Crimea, non-government controlled areas of the Kherson and Zaporizhzhia oblasts of Ukraine, the so-called Donetsk People&rsquo;s Republic,
the so-called Luhansk People&rsquo;s Republic, Cuba, Iran, North Korea and Syria (each, a &ldquo;<U>Sanctioned Country</U>&rdquo;); and
the Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise
make available such proceeds to any Subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities
of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund
or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by
any person (including any person participating in the transaction, whether as underwriter, initial purchaser, advisor, investor or otherwise)
of Sanctions. For the past five years, the Company and the Subsidiaries have not knowingly engaged in, are not now knowingly engaged in
and will not engage in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject
or the target of Sanctions or with any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(xx)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>(A) There has been no security breach or incident, unauthorized access or disclosure, or other compromise of or relating to the
Company&rsquo;s or its Subsidiaries&rsquo; information technology and computer systems, networks, hardware, software, data and databases
(including the data and information of their respective customers, employees, suppliers, vendors and any third party data maintained,
processed or stored by the Company and its Subsidiaries, and any such data processed or stored by third parties on behalf of the Company
and its Subsidiaries), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;), except as would not, in the case
of this clause (A), individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (B) neither the Company
nor its Subsidiaries have been notified of, and each of them have no knowledge of any event or condition that would reasonably be expected
to result in, any security breach or incident, unauthorized access or disclosure or other compromise to their IT Systems and Data, except
as would not, in the case of this clause (B), individually or in the aggregate, reasonably be expected to have a Material Adverse Effect,
and (C) the Company and its Subsidiaries have implemented backup and disaster recovery technology reasonably consistent in all material
respects with industry standards and practices or otherwise as the Company generally deems reasonably adequate for its and its Subsidiaries&rsquo;
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Purchase, Sale and Delivery of
the Notes</U>. On the basis of the representations, warranties, agreements and covenants herein contained and subject to the terms and
conditions herein set forth, the Company and the Subsidiary Guarantor agree to issue and sell to the Underwriters, and the Underwriters,
acting severally and not jointly, agree to purchase the Securities in the respective amounts set forth on <U>Schedule 1</U> hereto from
the Company at a price equal to 98.518% of their principal amount, plus accrued interest, if any, from June 20, 2025 to the
Closing Date. One or more certificates in definitive form for the Securities that the Underwriters have agreed to purchase hereunder,
and in such denomination or denominations and registered in such name or names as the Underwriters request upon notice to the Company
of at least 48 hours (but not less than one business day) prior to the Closing Date, shall be delivered by or on behalf of the Company
and the Subsidiary Guarantor to the Underwriters, against payment by or on behalf of the Underwriters of the purchase price therefor by
wire transfer (same day funds), to such account or accounts as the Company shall specify in writing prior to the Closing Date, or by such
means as the parties hereto shall agree prior to the Closing Date. Such delivery of and payment for the Securities shall be made at the
offices of Skadden, Arps, Slate, Meagher &amp; Flom LLP, New York, New York at 10:00 a.m., New York time, on June 20, 2025 or at
such other place, time or date as the Underwriters, on the one hand, and the Company, on the other hand, may agree upon, such time and
date of delivery against payment being herein referred to as the &ldquo;<U>Closing Date</U>.&rdquo; The Company and the Subsidiary Guarantor
will make such certificate or certificates for the Securities available for checking and packaging by the Underwriters at the offices
of Skadden, Arps, Slate, Meagher &amp; Flom LLP, One Manhattan West, New York, New York 10001, or at such other place as the Representatives
may designate, at least 24 hours prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Offering by the Underwriters</U>.
The Underwriters propose to make a public offering of the Securities at the price and upon the terms set forth in the Pricing Disclosure
Package and the Prospectus as soon as practicable after this Agreement is entered into and as in the judgment of the Underwriters is advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Covenants of the Company</U>. Each
of the Company and the Subsidiary Guarantor, as the case may be, jointly and severally, covenants and agrees with the Underwriters as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company and the Subsidiary Guarantor will file the final Prospectus with the Commission within the time periods specified by
Rule 424(b) and Rule 430A, 430B or 430C under the Act, will file any Issuer Free Writing Prospectus (including the Term Sheet in the form
of Annex B hereto) to the extent required by Rule 433 under the Act; and the Company will file promptly all reports and any definitive
proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d)
of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection
with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus
(to the extent not previously delivered) to the Underwriters in New York City as promptly as practicable following the date of this Agreement
in such quantities as the Representatives may reasonably request. The Company will pay the registration fees for this offering within
the time period required by Rule 456(b)(1)(i) under the Act (without giving effect to the proviso therein) and in any event prior to the
Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before
filing any amendment or supplement to the Registration Statement or the Prospectus, whether before or after the time that the Registration
Statement becomes effective, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer
Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any
such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object.
The Company will promptly, upon the reasonable request of the Underwriters or counsel for the Underwriters, make any amendments or supplements
to the Pricing Disclosure Package and the Prospectus that may be necessary or advisable in connection with the sale of the Securities
by the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company and the Subsidiary Guarantor will cooperate with the Underwriters to arrange for the qualification of the Securities
for offering and sale under the securities or &ldquo;Blue Sky&rdquo; laws of such U.S. jurisdictions as the Underwriters may reasonably
designate and will continue such qualifications in effect for as long as may be necessary to complete the distribution of the Securities;
<U>provided</U>, <U>however</U>, that in connection therewith, neither the Company nor the Subsidiary Guarantor shall be required to qualify
as a foreign corporation or to execute a general consent to service of process in any jurisdiction or subject itself to taxation in excess
of a nominal dollar amount in any such jurisdiction where it is not then so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company will advise the Representatives promptly, and confirm such advice in writing, (i) when any amendment to the Registration
Statement has been filed or becomes effective; (ii) when any supplement to the Prospectus or any amendment to the Prospectus or any Issuer
Free Writing Prospectus has been filed; (iii) of any request by the Commission for any amendment to the Registration Statement or any
amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or
any other request by the Commission for any additional information; (iv) of the issuance by the Commission of any order suspending the
effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus or the Prospectus or the
initiation or threatening of any proceeding for that purpose or pursuant to Section 8A of the Act; (v) of the occurrence of any event
within the Prospectus Delivery Period (as defined below) as a result of which the Prospectus, the Pricing Disclosure Package or any Issuer
Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances existing when
the Prospectus, the Pricing Disclosure Package or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading;
(vi) of the receipt by the Company of any notice of objection of the Commission to the use of the Registration Statement or any post-effective
amendment thereto pursuant to Rule 401(g)(2) under the Act; and (vii) of the receipt by the Company of any notice with respect to any
suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding
for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness
of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus or the Prospectus or suspending any such
qualification of the Securities and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If at any time prior to the Closing Date (i) any event shall occur or condition shall exist as a result of which any of the Pricing
Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or
(ii) it is necessary to amend or supplement the Pricing Disclosure Package to comply with applicable law, the Company will immediately
notify the Underwriters thereof and forthwith prepare and, subject to paragraph (b) above, file with the Commission (to the extent required)
and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to the Pricing
Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that
the statements in any of the Pricing Disclosure Package as so amended or supplemented (including such documents to be incorporated by
reference therein) will not, in the light of the circumstances under which they were made, be misleading or so that the Pricing Disclosure
Package will comply with law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company will deliver, without charge, to each Underwriter (i) a conformed copy of the Registration Statement as originally
filed and each amendment thereto, in each case including all exhibits and consents filed therewith and (ii) during the Prospectus Delivery
Period, as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein)
and each Issuer Free Writing Prospectus as the Representatives may reasonably request. As used herein, the term &ldquo;<U>Prospectus Delivery
Period</U>&rdquo; means such period of time after the first date of the public offering of the Securities as in the reasonable opinion
of counsel for the Underwriters a prospectus relating to the Securities is required by law to be delivered (or required to be delivered
but for Rule 172 under the Act) in connection with sales of the Securities by any Underwriter or dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If during the Prospectus Delivery Period (i) any event shall occur or condition shall exist as a result of which the Prospectus
as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is
delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with applicable law,
the Company will immediately notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the
Commission and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to
the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the
statements in the Prospectus as so amended or supplemented, including any documents to be incorporated by reference, will not, in the
light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply
with law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company will apply the net proceeds from the sale of the Notes as set forth under &ldquo;Use of proceeds&rdquo; in the Pricing
Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company will make generally available to its security holders and the Representatives (by filing under the Exchange Act or
otherwise) as soon as practicable an earning statement that satisfies the provisions of Section 11(a) of the Act and Rule 158 of the Commission
promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after
the &ldquo;effective date&rdquo; (as defined in Rule 158) of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company will use commercially reasonable efforts to permit the Securities to be eligible for clearance and settlement through
The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>During the period from the date hereof through and including the Closing Date, the Company will not, without the prior written
consent of the Representatives, directly or indirectly, issue, sell, offer to contract or grant any option to sell, pledge, transfer or
otherwise dispose of any debt securities or securities exchangeable for or convertible into debt securities, provided that the foregoing
shall not apply to the sale of the Securities under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company has not taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result
in any stabilization or manipulation of the price of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Expenses</U>. The Company and the
Subsidiary Guarantor, jointly and severally, agree to pay all costs and expenses incident to the performance of their obligations under
this Agreement, whether or not the transactions contemplated herein are consummated or this Agreement is terminated pursuant to Section
11 hereof, including all costs and expenses incident to (i) the printing, word processing or other production of documents with respect
to the transactions contemplated hereby, including any costs of printing and filing under the Act of the Registration Statement, any Issuer
Free Writing Prospectus, the Pricing Disclosure Package and the Prospectus and any exhibit, amendment or supplement thereto, and any &ldquo;Blue
Sky&rdquo; memoranda, (ii) all arrangements relating to the delivery to the Underwriters of copies of the foregoing documents, (iii) the
fees and disbursements of the counsel, the accountants and any other experts or advisors retained by the Company, (iv) preparation (including
printing), issuance and delivery to the Underwriters of the Securities, (v) the qualification of the Securities under state securities
and &ldquo;Blue Sky&rdquo; laws, including filing fees and fees and disbursements of counsel for the Underwriters, (vi) expenses in connection
with the &ldquo;road show,&rdquo; if any, and any other meetings with prospective investors in the Securities, (vii) fees and expenses
of the Trustee, including fees and expenses of counsel, (viii) all expenses and application fees incurred in connection with any filing
with, and clearance of the offering by the Financial Industry Regulatory Authority, (ix) all expenses and application fees incurred in
connection with the approval of the Securities for book-entry transfer by the Depository Trust Company; and (x) any fees charged by investment
rating agencies for the rating of the Securities. If the sale of the Securities provided for herein is not consummated because any condition
to the obligations of the Underwriters set forth in Section 7 hereof is not satisfied, because this Agreement is terminated or because
of any failure, refusal or inability on the part of the Company or the Subsidiary Guarantor to perform all obligations and satisfy all
conditions on their part to be performed or satisfied hereunder (other than solely by reason of a default by the Underwriters of their
obligations hereunder after all conditions hereunder have been satisfied in accordance herewith), the Company and the Subsidiary Guarantor
agree to promptly reimburse the Underwriters upon demand for all reasonable and documented out-of-pocket expenses (including the fees,
disbursements and charges of Skadden, Arps, Slate, Meagher &amp; Flom LLP, counsel for the Underwriters), that shall have been incurred
by the Underwriters in connection with the proposed purchase and sale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Conditions of the Underwriters&rsquo;
Obligations</U>. The obligation of the Underwriters to purchase and pay for the Securities shall, in their sole discretion, be subject
to the satisfaction or waiver of the following conditions on or prior to the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose, pursuant
to Rule 401(g)(2) or pursuant to Section 8A under the Act shall be pending before or threatened by the Commission; the Prospectus and
each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Act (in the case of an Issuer Free Writing
Prospectus, to the extent required by Rule 433 under the Act) and in accordance with Section 5(a) hereof; and all requests by the Commission
for additional information shall have been complied with to the reasonable satisfaction of the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>On the Closing Date, the Representatives shall have received the opinions, dated as of the Closing Date and addressed to the Underwriters,
of (i) Bryan Cave Leighton Paisner LLP, counsel for the Company and the Subsidiary Guarantor, and (ii) Shapiro Sher Guinot and Sandler,
P.A., Maryland counsel to the Company, in substantially the forms provided to the Representatives concurrently with the execution of this
Agreement and to such further effect as the Underwriters shall reasonably request at a reasonable time prior to the Closing Date. Such
counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon
certificates of officers of the Company and the Subsidiary Guarantor and certificates of public officials, copies of which shall have
been provided to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>On the Closing Date, the Representatives shall have received the opinion, in form and substance satisfactory to the Representatives,
dated as of the Closing Date and addressed to the Underwriters, of Skadden, Arps, Slate, Meagher &amp; Flom LLP, counsel for the Underwriters,
with respect to certain legal matters relating to this Agreement and such other related matters as the Underwriters may reasonably require.
Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper,
upon certificates of officers of the Company and the Subsidiary Guarantor and certificates of public officials, copies of which shall
have been provided to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>On the date hereof, the Representatives shall have received from Ernst &amp; Young LLP, independent registered public accountants
for the Company, a comfort letter dated the date hereof, in form and substance satisfactory to counsel for the Underwriters with respect
to the audited, unaudited and pro forma financial information in the Pricing Disclosure Package. On the Closing Date, the Representatives
shall have received from Ernst &amp; Young LLP, independent registered public accountants for the Company, a comfort letter dated the
Closing Date, in form and substance satisfactory to counsel for the Underwriters, which shall refer to the comfort letter dated the date
hereof and reaffirm or update as of a more recent date the information stated in the comfort letter dated the date hereof and similarly
address the audited, unaudited and pro forma financial information contained in or incorporated by reference in the Registration Statement,
the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The representations and warranties of the Company and the Subsidiary Guarantor contained in this Agreement shall be true and correct
on and as of the Time of Execution and on and as of the Closing Date as if made on and as of the Closing Date; the statements of the Company&rsquo;s
and the Subsidiary Guarantor&rsquo;s officers made pursuant to any certificate delivered in accordance with the provisions hereof shall
be true and correct on and as of the date made and on and as of the Closing Date; the Company and the Subsidiary Guarantor shall have
performed all covenants and agreements and satisfied all conditions on their part to be performed or satisfied hereunder at or prior to
the Closing Date; and, except as described in the Pricing Disclosure Package (exclusive of any amendment or supplement thereto after the
date hereof), subsequent to the date of the most recent financial statements in such Pricing Disclosure Package, there shall have been
no event or development, and no information shall have become known, that, individually or in the aggregate, has or would be reasonably
likely to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sale of the Securities hereunder shall not be enjoined (temporarily or permanently) on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subsequent to the date of the most recent financial statements in the Pricing Disclosure Package (exclusive of any amendment or
supplement thereto after the date hereof), none of the Company or any of the Subsidiaries shall have sustained any loss or interference
with respect to its business or properties from fire, flood, hurricane, accident or other calamity, whether or not covered by insurance,
or from any strike, labor dispute, slow down or work stoppage or from any legal or governmental proceeding, order or decree, which loss
or interference, individually or in the aggregate, has or would be reasonably likely to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Representatives shall have received certificates of the Company and the Subsidiary Guarantor, dated the Closing Date, signed
on behalf of the Company or the Subsidiary Guarantor by its Chairman of the Board, Chief Executive Officer, President or any Vice President,
the Chief Financial Officer and the Chief Accounting Officer, to the effect that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the representations and warranties of the Company or the Subsidiary Guarantor contained in this Agreement are true and correct
on and as of the Time of Execution and on and as of the Closing Date, and the Company or the Subsidiary Guarantor has performed all covenants
and agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&#8239;&#8239;&#8239;&#8239;(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>at the Closing Date, since the date hereof or since the date of the most recent financial statements in the Pricing Disclosure
Package (exclusive of any amendment or supplement thereto after the date hereof), no event or development has occurred, and no information
has become known to the Company or the Subsidiary Guarantor, that, individually or in the aggregate, has or would be reasonably likely
to have a Material Adverse Effect; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&#8239;&#8239;&#8239;&#8239;(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the sale of the Securities hereunder has not been enjoined (temporarily or permanently).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>On each of the date hereof and on the Closing Date, the Representatives shall have received a certificate of the Chief Financial
Officer of the Company, on behalf of the Company for itself and its Subsidiaries, dated the date hereof or the Closing Date (as applicable),
substantially in the form set forth in <U>Exhibit A</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>On the Closing Date, the Representatives shall have received the Indenture, as amended or supplemented from time to time, executed
by the Company, the Subsidiary Guarantor and the Trustee and the Indenture shall be in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Securities shall be eligible for clearance and settlement through The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">On or before the Closing Date, the Representatives
and counsel for the Underwriters shall have received such further documents, opinions, certificates, letters and schedules or instruments
relating to the business, corporate, legal and financial affairs of the Company and the Subsidiaries as they shall have heretofore reasonably
requested from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">All such documents, opinions, certificates, letters,
schedules or instruments delivered pursuant to this Agreement will comply with the provisions hereof only if they are reasonably satisfactory
in all material respects to the Underwriters and counsel for the Underwriters. The Company and the Subsidiary Guarantor shall furnish
to the Underwriters such conformed copies of such documents, opinions, certificates, letters, schedules and instruments in such quantities
as the Underwriters shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Certain Agreements of the Underwriters</U>.
Each Underwriter hereby represents and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>It has not and will not use, authorize use of, refer to, or participate in the planning for use of, any &ldquo;<U>free writing
prospectus</U>&rdquo;, as defined in Rule 405 under the Act (which term includes use of any written information furnished to the Commission
by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than
(i) a free writing prospectus that, solely as a result of use by such Underwriter, would not trigger an obligation to file such free writing
prospectus with the Commission pursuant to Rule 433 under the Act, (ii) any Issuer Free Writing Prospectus listed on Annex B or prepared
pursuant to Section 2(a), Section 5(a) or Section 5(b) above, or (iii) any free writing prospectus prepared by such Underwriter and approved
by the Company in advance in writing. Notwithstanding the foregoing, the Underwriters may use the Term Sheet in the form of Annex B hereto
without the consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Indemnification and Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company and the Subsidiary Guarantor, jointly and severally, agree to indemnify and hold harmless each Underwriter, its directors
and officers and each person, if any, who controls any Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange
Act against any losses, claims, damages or liabilities to which any Underwriter or such director, officer or controlling person may become
subject under the Act, the Exchange Act or otherwise, insofar as any such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of, or are based upon, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&#8239;&#8239;&#8239;&#8239;(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any untrue statement or alleged untrue statement made by the Company or the Subsidiary Guarantor in Section 2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&#8239;&#8239;&#8239;&#8239;(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission
or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, not misleading;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement
thereto), any Issuer Free Writing Prospectus, any Pricing Disclosure Package or any non-deal road show prior to the offering of the Securities,
or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and will reimburse, as incurred, the Underwriters and each such director,
officer or controlling person for any reasonable legal or other documented expenses incurred by the Underwriters or such director, officer
or controlling person in connection with investigating, defending against or appearing as a third-party witness in connection with any
such loss, claim, damage, liability or action; <U>provided</U>, <U>however</U>, the Company and the Subsidiary Guarantor will not be liable
in any such case to the extent that any such loss, claim, damage, or liability arises out of, or is based upon, any untrue statement or
alleged untrue statement or omission or alleged omission made in the Registration Statement, the Pricing Disclosure Package or the Prospectus
or any amendment or supplement thereto in reliance upon and in conformity with written information concerning the Underwriters furnished
to the Company by the Underwriters through the Representatives specifically for use therein, which information is described in Section
12 hereof. The indemnity provided for in this Section 9 will be in addition to any liability that the Company and the Subsidiary Guarantor
may otherwise have to the indemnified parties. The Company and the Subsidiary Guarantor shall not be liable under this Section 9 for any
settlement of any claim or action effected without their prior written consent, which shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company and the Subsidiary Guarantor, their
respective directors, their respective officers who signed the Registration Statement and each person, if any, who controls the Company
and the Subsidiary Guarantor within the meaning of Section 15 of the Act or Section 20 of the Exchange Act against any losses, claims,
damages or liabilities to which the Company and the Subsidiary Guarantor or any such director, officer or controlling person may become
subject under the Act, the Exchange Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof)
arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein, not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact contained in
the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus or any Pricing Disclosure Package, or caused
by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement
or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information concerning
such Underwriter, furnished to the Company by such Underwriter through the Representatives specifically for use therein, which information
is described in Section 12 hereof; and subject to the limitation set forth immediately preceding this clause, will reimburse, as incurred,
any reasonable legal or other documented expenses incurred by the Company and the Subsidiary Guarantor or any such director, officer or
controlling person in connection with investigating or defending against or appearing as a third party witness in connection with any
such loss, claim, damage, liability or action in respect thereof. The indemnity provided for in this Section 9 will be in addition to
any liability that the Underwriters may otherwise have to the indemnified parties. The Underwriters shall not be liable under this Section
9 for any settlement of any claim or action effected without their consent, which shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of any action for which such
indemnified party is entitled to indemnification under this Section 9, such indemnified party will, if a claim in respect thereof is to
be made against the indemnifying party under this Section 9, notify the indemnifying party of the commencement thereof in writing; but
the omission to so notify the indemnifying party (i) will not relieve it from any liability under paragraph (a) or (b) above unless and
to the extent such failure results in the forfeiture by the indemnifying party of substantial rights and defenses and (ii) will not, in
any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided
in paragraphs (a) and (b) above. In case any such action is brought against any indemnified party and it notifies the indemnifying party
of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, jointly
with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified
party; <U>provided</U>, <U>however</U>, that if (i) the use of counsel chosen by the indemnifying party to represent the indemnified party
would present such counsel with a conflict of interest, (ii) the defendants in any such action include both the indemnified party and
the indemnifying party and the indemnified party shall have been advised by counsel that there may be one or more legal defenses available
to it and/or other indemnified parties that are different from or additional to those available to the indemnifying party or (iii) the
indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party
within a reasonable time after receipt by the indemnifying party of notice of the institution of such action, then, in each such case,
the indemnifying party shall not have the right to direct the defense of such action on behalf of such indemnified party or parties and
such indemnified party or parties shall have the right to select separate counsel to defend such action on behalf of such indemnified
party or parties. After notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof
and approval by such indemnified party of counsel appointed to defend such action, the indemnifying party will not be liable to such indemnified
party under this Section 9 for any legal or other expenses, other than reasonable costs of investigation, subsequently incurred by such
indemnified party in connection with the defense thereof, unless (i) the indemnified party shall have employed separate counsel in accordance
with the proviso to the immediately preceding sentence (it being understood, however, that in connection with such action the indemnifying
party shall not be liable for the expenses of more than one separate counsel (in addition to local counsel) in any one action or separate
but substantially similar actions in the same jurisdiction arising out of the same general allegations or circumstances, designated by
the Underwriters in the case of paragraph (a) of this Section 9 or the Company and the Subsidiary Guarantor in the case of paragraph (b)
of this Section 9, representing the indemnified parties under such paragraph (a) or paragraph (b), as the case may be, who are parties
to such action or actions) or (ii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party
at the expense of the indemnifying party. All fees and expenses reimbursed pursuant to this paragraph (c) shall be reimbursed as they
are incurred. After such notice from the indemnifying party to such indemnified party, the indemnifying party will not be liable for the
costs and expenses of any settlement of such action effected by such indemnified party without the prior written consent of the indemnifying
party (which consent shall not be unreasonably withheld), unless such indemnified party waived in writing its rights under this Section
9, in which case the indemnified party may effect such a settlement without such consent. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement or compromise of any pending or threatened proceeding in respect of which
any indemnified party is or could have been a party, or indemnity could have been sought hereunder by any indemnified party, unless such
settlement (A) includes an unconditional written release of the indemnified party, in form and substance reasonably satisfactory to the
indemnified party, from all liability on claims that are the subject matter of such proceeding and (B) does not include any statement
as to an admission of fault, culpability or failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In circumstances in which the indemnity agreement provided for in the preceding paragraphs of this Section 9 is unavailable to,
or insufficient to hold harmless, an indemnified party in respect of any losses, claims, damages or liabilities (or actions in respect
thereof) referred to herein, each indemnifying party, in order to provide for just and equitable contribution, shall contribute to the
amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof)
in such proportion as is appropriate to reflect (i) the relative benefits received by the indemnifying party or parties on the one hand
and the indemnified party on the other from the offering of the Securities or (ii) if the allocation provided by the foregoing clause
(i) is not permitted by applicable law, not only such relative benefits but also the relative fault of the indemnifying party or parties
on the one hand and the indemnified party on the other in connection with the statements or omissions or alleged statements or omissions
that resulted in such losses, claims, damages or liabilities (or actions in respect thereof). The relative benefits received by the Company
and the Subsidiary Guarantor on the one hand and any Underwriter on the other shall be deemed to be in the same proportion as the total
proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions
received by such Underwriter. The relative fault of the parties shall be determined by reference to, among other things, whether the untrue
or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied
by the Company and the Subsidiary Guarantor on the one hand, or such Underwriter on the other, the parties&rsquo; relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission or alleged statement or omission, and any other
equitable considerations appropriate in the circumstances. The Company, the Subsidiary Guarantor and the Underwriters agree that it would
not be equitable if the amount of such contribution were determined by pro rata or per capita allocation or by any other method of allocation
that does not take into account the equitable considerations referred to in the first sentence of this paragraph (d). Notwithstanding
any other provision of this paragraph (d), no Underwriter shall be obligated to make contributions hereunder that in the aggregate exceed
the total underwriting discounts, commissions and other compensation received by such Underwriter under this Agreement, less the aggregate
amount of any damages that such Underwriter has otherwise been required to pay by reason of the untrue or alleged untrue statements or
the omissions or alleged omissions to state a material fact, and no person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
For purposes of this paragraph (d), each person, if any, who controls an Underwriter within the meaning of Section 15 of the Act or Section
20 of the Exchange Act and each director and each officer of the Underwriters shall have the same rights to contribution as the Underwriters,
and each director of the Company and the Subsidiary Guarantor, each officer of the Company or the Subsidiary Guarantor who signed the
Registration Statement and each person, if any, who controls the Company and the Subsidiary Guarantor within the meaning of Section 15
of the Act or Section 20 of the Exchange Act shall have the same rights to contribution as the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Survival Clause</U>. The respective representations, warranties,
agreements, covenants, indemnities and other statements of the Company and the Subsidiary Guarantor, their respective officers and the
Underwriters set forth in this Agreement or made by or on behalf of them pursuant to this Agreement shall remain in full force and effect,
regardless of (i) any investigation made by or on behalf of the Company and the Subsidiary Guarantor, any of their officers or directors,
the Underwriters or any of their officers or directors or any controlling person referred to in Section 9 hereof and (ii) delivery of
and payment for the Securities. The respective agreements, covenants, indemnities and other statements set forth in Sections 5, 6, 9,
10, 15 and Section 16 hereof shall remain in full force and effect, regardless of any termination or cancellation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Agreement may be terminated in the sole discretion of the Underwriters by notice to the Company and the Subsidiary Guarantor
given prior to the Closing Date in the event that the Company and the Subsidiary Guarantor shall have failed, refused or been unable to
perform all obligations and satisfy all conditions on their part to be performed or satisfied hereunder at or prior thereto or, if at
or prior to the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any of the Company or the Subsidiaries shall have sustained any loss or interference with respect to its businesses or properties
from fire, flood, hurricane, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute, slow
down or work stoppage or any legal or governmental proceeding, which loss or interference, in the sole judgment of the Underwriters, has
had or has a Material Adverse Effect, or there shall have been, in the sole judgment of the Underwriters, any event or development that,
individually or in the aggregate, has or could be reasonably likely to have a Material Adverse Effect (including, without limitation,
a change in control of the Company or the Subsidiaries), except, in each case, as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&#8239;&#8239;&#8239;&#8239;(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>trading in securities of the Company or in securities generally on the NYSE, NYSE American or the NASDAQ National Market shall
have been suspended or materially limited or minimum or maximum prices shall have been established on any such exchange or market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&#8239;&#8239;&#8239;&#8239;(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>a banking moratorium shall have been declared by New York or United States authorities or a material disruption in commercial banking
or securities settlement or clearance services in the United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there shall have been (A) an outbreak or escalation of hostilities between the United States and any foreign power, (B) an outbreak
or escalation of any other insurrection or armed conflict involving the United States or any other national or international calamity
or emergency or (C) any material change in the financial markets of the United States which, in the case of (A), (B) or (C) above and
in the sole judgment of the Underwriters, makes it impracticable or inadvisable to proceed with the offering or the delivery of the Securities
as contemplated by the Pricing Disclosure Package and the Prospectus; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&#8239;&#8239;&#8239;&#8239;(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any securities of the Company shall have been downgraded by any nationally recognized statistical rating organization or any such
organization shall have publicly announced that it has under surveillance or review, or has changed its outlook with respect to, its ratings
of any securities of the Company (other than an announcement with positive implications of a possible upgrading).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Termination of this Agreement pursuant to this Section 11 shall be without liability of any party to any other party except as
provided in Section 10 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Information Supplied by the Underwriters</U>. The statements
set forth (i) in the last paragraph on the front cover page, and (ii) in the fifth paragraph under the heading &ldquo;Underwriting,&rdquo;
it being understood that there are fifteen paragraphs prior to the sub-heading &ldquo;Other Relationships (conflicts of interest)&rdquo;
under &ldquo;Underwriting&rdquo; in the Pricing Disclosure Package and the Prospectus, as well as the marketing names of the Underwriters
contained in the Pricing Disclosure Package and the Prospectus, constitute the only information furnished by the Underwriters to the Company
for the purposes of Sections 2(a) and 9 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Notices</U>. All communications hereunder shall be in
writing (including via fax or e-mail) and, if sent to the Underwriters, shall be mailed or delivered, electronically or otherwise, to:
(i) Wells Fargo Securities, Inc., 550 South Tryon Street, 5th Floor, Charlotte, North Carolina 28202, Attention: Transaction Management,
Email: tmgcapitalmarkets@wellsfargo.com, (ii) BofA Securities, Inc., 114 W 47th Street, NY8-114-07-01, New York, New York 10036, Attention:
High Grade Transaction Management/Legal, Fax: 646-855-5958, (iii) Credit Agricole Securities (USA) Inc., 1301 Avenue of the Americas,
8th Floor, New York, New York 10019, Attention: Debt Capital Markets, E-mail: DCMNewYork@ca-cib.com, (iv) J.P. Morgan Securities LLC,
383 Madison Avenue, New York, New York 10179, Attention: Investment Grade Syndicate Desk, Facsimile: 212-834-6081 and (v) if sent to the
Company, shall be mailed or delivered, electronically or otherwise, to 303 International Circle, Suite 200, Hunt Valley, Maryland, 21030,
Attention: Robert O. Stephenson, Chief Financial Officer, E-mail: BStephenson@OmegaHealthCare.com; with a copy to Bryan Cave Leighton
Paisner LLP, One Atlantic Center, Fourteenth Floor, 1201 W. Peachtree Street, NW, Atlanta, Georgia 30309-3488, Attention: Eliot Robinson,
E-mail: eliot.robinson@bclplaw.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">All such notices and communications shall be deemed
to have been duly given: when delivered by hand, if personally delivered; ten business days after being deposited in the mail, postage
prepaid, if mailed; one business day after being timely delivered to a next-day air courier; and when sent by fax or e-mail (provided
affirmative confirmation of receipt is obtained from the recipient) if sent during normal business hours of the recipient, and on the
next business day if sent after normal business hours of the recipient (provided affirmative confirmation of receipt is obtained from
the recipient).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Successors</U>. This Agreement shall inure to the benefit
of and be binding upon the Underwriters, the Company, the Subsidiary Guarantor and their respective successors and legal representatives,
and nothing expressed or mentioned in this Agreement is intended or shall be construed to give any other person any legal or equitable
right, remedy or claim under or in respect of this Agreement, or any provisions herein contained; this Agreement and all conditions and
provisions hereof being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person
except that (i) the indemnities of the Company and the Subsidiary Guarantor contained in Section 9 of this Agreement shall also be for
the benefit of any person or persons who control the Underwriters within the meaning of Section 15 of the Act or Section 20 of the Exchange
Act and any directors and officers of the Underwriters and (ii) the indemnities of the Underwriters contained in Section 9 of this Agreement
shall also be for the benefit of the directors of the Company and the Subsidiary Guarantor, their officers and any person or persons who
control the Company and the Subsidiary Guarantor within the meaning of Section 15 of the Act or Section 20 of the Exchange Act. No purchaser
of Securities from the Underwriters will be deemed a successor because of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>APPLICABLE LAW</U>. THE VALIDITY AND INTERPRETATION OF
THIS AGREEMENT, AND THE TERMS AND CONDITIONS SET FORTH HEREIN, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE
OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED WHOLLY THEREIN, WITHOUT GIVING EFFECT TO ANY PROVISIONS THEREOF RELATING
TO CONFLICTS OF LAW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>TRIAL BY JURY</U>. THE COMPANY (ON ITS BEHALF AND, TO
THE EXTENT PERMITTED BY APPLICABLE LAW, ON BEHALF OF ITS SECURITY HOLDERS AND AFFILIATES), THE SUBSIDIARY GUARANTOR AND EACH OF THE UNDERWRITERS
HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>CONSENT TO JURISDICTION</U>.&#8239; ANY LEGAL SUIT, ACTION
OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (&ldquo;RELATED PROCEEDINGS&rdquo;)
MAY BE INSTITUTED IN THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA LOCATED IN THE CITY AND COUNTY OF NEW YORK OR THE COURTS OF THE
STATE OF NEW YORK IN EACH CASE LOCATED IN THE CITY AND COUNTY OF NEW YORK (COLLECTIVELY, THE &ldquo;SPECIFIED COURTS&rdquo;), AND EACH
PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION (EXCEPT FOR SUITS, ACTIONS, OR PROCEEDINGS INSTITUTED IN REGARD TO THE ENFORCEMENT
OF A JUDGMENT OF ANY SPECIFIED COURT IN A RELATED PROCEEDING (A &ldquo;RELATED JUDGMENT&rdquo;), AS TO WHICH SUCH JURISDICTION IS NON-EXCLUSIVE)
OF THE SPECIFIED COURTS IN ANY RELATED PROCEEDING.&#8239; SERVICE OF ANY PROCESS, SUMMONS, NOTICE OR DOCUMENT BY MAIL TO SUCH PARTY&rsquo;S
ADDRESS SET FORTH ABOVE SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY RELATED PROCEEDING BROUGHT IN ANY SPECIFIED COURT.&#8239; THE PARTIES
IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY RELATED PROCEEDING IN THE SPECIFIED COURTS AND IRREVOCABLY
AND UNCONDITIONALLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SPECIFIED COURT THAT ANY RELATED PROCEEDING BROUGHT IN ANY SPECIFIED
COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Default by an Underwriter</U>. If any one or more Underwriters
shall fail to purchase and pay for any of the Notes agreed to be purchased by such Underwriter hereunder and such failure to purchase
shall constitute a default in the performance of its or their obligations under this Agreement, the remaining Underwriters shall be obligated
severally to take up and pay for (in the respective proportions which the principal amount of Notes set forth opposite their names in
<U>Schedule 1</U> hereto bears to the aggregate principal amount of Notes set forth opposite the names of all the remaining Underwriters)
the Notes which the defaulting Underwriter or Underwriters agreed but failed to purchase; <U>provided</U>, <U>however</U>, that in the
event that the aggregate principal amount of Notes which the defaulting Underwriter or Underwriters agreed but failed to purchase shall
exceed 10% of the aggregate principal amount of Notes set forth in <U>Schedule 1</U> hereto, the Company shall be entitled to a further
period of 36 hours within which to procure another party or parties reasonably satisfactory to the nondefaulting Underwriter or Underwriters
to purchase no less than the amount of such unpurchased Notes that exceeds 10% of the principal amount thereof upon such terms herein
set forth. If, however, the Company shall not have completed such arrangements within 72 hours after such default and the principal amount
of such unpurchased Notes exceeds 10% of the principal amount of such Notes to be purchased on such date, then this Agreement will terminate
without liability to any nondefaulting Underwriter or the Company. In the event of a default by any Underwriter as set forth in this Section
18, the Closing Date shall be postponed for such period, not exceeding five business days, as the Representatives, the Company and their
counsel shall determine in order that the required changes in the Pricing Disclosure Package and the Prospectus or in any other documents
or arrangements may be effected. Nothing contained in this Agreement shall relieve any defaulting Underwriter of its liability, if any,
to the Company or any nondefaulting Underwriter for damages occasioned by its default hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>No Advisory or Fiduciary Responsibility</U>. The Company
and the Subsidiary Guarantor acknowledge and agree that (i) the offering of the Securities pursuant to this Agreement is an arm&rsquo;s-length
commercial transaction between the Company and the Subsidiary Guarantor, on the one hand, and the Underwriters, on the other, (ii) in
connection therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent
or fiduciary of the Company or the Subsidiary Guarantor, (iii) no Underwriter has assumed an advisory or fiduciary responsibility in favor
of the Company or the Subsidiary Guarantor with respect to the offering contemplated hereby or the process leading thereto (irrespective
of whether such Underwriter has advised or is currently advising the Company or the Subsidiary Guarantor on other matters) or any other
obligation to the Company or the Subsidiary Guarantor except the obligations expressly set forth in this Agreement and (iv) the Company
and the Subsidiary Guarantor have consulted their own legal and financial advisors to the extent they deemed appropriate. The Company
and the Subsidiary Guarantor agree that they will not claim that any Underwriter has rendered advisory services of any nature or respect,
or owes a fiduciary or similar duty to the Company or the Subsidiary Guarantor, in connection with such transaction or the process leading
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Recognition of the U.S. Special Resolution Regimes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to
the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and
obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">As used in this Section 20, &ldquo;<U>BHC Act Affiliate</U>&rdquo;
has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k);
 &ldquo;<U>Covered Entity</U>&rdquo; means any of the following: (i) a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted
in accordance with, 12 C.F.R. &sect; 252.82(b), (ii) a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &sect; 47.3(b) or (iii) a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &sect; 382.2(b); &ldquo;<U>Default Right</U>&rdquo; has the meaning assigned to that term in, and shall be interpreted in accordance
with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable; and &ldquo;<U>U.S. Special Resolution Regime</U>&rdquo; means each
of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform
and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Counterparts</U>. This Agreement may be executed in two
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act
of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., <U>www.docusign.com</U>)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">If the foregoing correctly sets forth our understanding,
please indicate your acceptance thereof in the space provided below for that purpose, whereupon this letter shall constitute a binding
agreement between the Company, the Subsidiary Guarantor and the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 39%; text-align: left"></TD><TD STYLE="text-align: justify; width: 61%">Very truly yours,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">OMEGA HEALTHCARE INVESTOR, INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">as the Company</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/
    Robert O. Stephenson</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-size: 10pt">Robert O. Stephenson</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Financial Officer, Treasurer and Assistant
    Secretary</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">OHI HEALTHCARE PROPERTIES LIMITED
    PARTNERSHIP</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">as the Subsidiary Guarantor</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/
    Robert O. Stephenson</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Robert O. Stephenson</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Financial Officer, Treasurer and Assistant
    Secretary</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Underwriting
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The foregoing Agreement is hereby confirmed and accepted
as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">WELLS FARGO SECURITIES, LLC</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Acting on behalf of itself</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">and as a Representative of</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the several Underwriters</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: WELLS FARGO SECURITIES, LLC</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Carolyn Hurley&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&#8239;Carolyn Hurley</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&#8239;&#8239;&#8239;Managing Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Underwriting
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BOFA SECURITIES, INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Acting on behalf of itself</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">and as a Representative of</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the several Underwriters</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: BOFA SECURITIES, INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Jon Klein&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&#8239;Jon Klein</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&#8239;&#8239;&#8239;Managing Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Underwriting
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CREDIT AGRICOLE SECURITIES (USA) INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Acting on behalf of itself</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">and as a Representative of</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the several Underwriters</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: CREDIT AGRICOLE SECURITIES (USA) INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ David C. Travis&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&#8239;David C. Travis</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&#8239;&#8239;&#8239;Managing Director</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Ivan Hrazdira&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&#8239;Ivan Hrazdira</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&#8239;&#8239;&#8239;Managing Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Underwriting
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 243pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">J.P. MORGAN SECURITIES LLC</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Acting on behalf of itself</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">and as a Representatives of</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the several Underwriters</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: J.P. MORGAN SECURITIES LLC</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Stephen L. Sheiner&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&#8239;Stephen L. Sheiner</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&#8239;&#8239;&#8239;Executive Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Underwriting
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>SCHEDULE 1 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwriters</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Principal Amount of <BR> Notes</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; text-align: left">Wells Fargo Securities, LLC</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 17%; font-size: 10pt; text-align: right">60,000,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">BofA Securities, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">60,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit Agricole Securities (USA) Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">60,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">J.P. Morgan Securities LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">60,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Citizens JMP Securities, LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">36,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Barclays Capital Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Huntington Securities, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">KeyBanc Capital Markets Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">M&amp;T Securities, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Mizuho Securities USA LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Morgan Stanley &amp; Co. LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">MUFG Securities Americas Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">RBC Capital Markets, LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Regions Securities LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Scotia Capital (USA) Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Truist Securities, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">24,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">BMO Capital Markets Corp.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">BNP Paribas Securities Corp.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Raymond James &amp; Associates, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">SMBC Nikko Securities America, Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Stifel, Nicolaus &amp; Company, Inc.</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,000,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 0.25in">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">600,000,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>ANNEX A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pricing Term Sheet substantially in the form of Annex B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>ANNEX B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Issuer Free Writing Prospectus, dated June 10,
2025<BR>
Filed Pursuant to Rule 433 under the Securities Act of 1933<BR>
Supplementing the Preliminary Prospectus Supplement<BR>
dated June 10, 2025<BR>
Registration Statement No. 333-282376</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Omega Healthcare Investors, Inc.<BR>
$600,000,000<BR>
5.200% Senior Notes due 2030<BR>
June 10, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Issuer:</B></TD>
    <TD STYLE="width: 57%; padding-top: 4.3pt; padding-bottom: 4.3pt">Omega Healthcare Investors, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Guarantees:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The notes will be fully and unconditionally guaranteed, jointly
and severally, by the Issuer&rsquo;s existing and future subsidiaries that guarantee unsecured indebtedness for money borrowed of the
Issuer in a principal amount at least equal to $50 million (including the Issuer&rsquo;s existing senior notes, unsecured revolving credit
facility and unsecured term loans).&nbsp;</P>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Expected Ratings*:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">Baa3 (Moody&rsquo;s) / BBB- (S&amp;P) / BBB- (Fitch)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Title of Securities:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">5.200% Senior Notes due 2030</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Aggregate Principal Amount:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">$600,000,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Trade Date:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">June 10, 2025</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Settlement Date:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">June 20, 2025 (T +7)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Final Maturity Date:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">July 1, 2030</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Issue Price to Public:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">99.118% plus accrued interest, if any, from June 20, 2025</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Gross Proceeds to Issuer:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">$594,708,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Coupon:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">5.200%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Yield to Maturity:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">5.402%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Benchmark Treasury:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">UST 4.000% due May 31, 2030</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Benchmark Treasury Yield:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">4.082%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Spread to Benchmark Treasury: </B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">+132 basis points</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Interest Payment Dates:</B></TD>
    <TD STYLE="width: 57%; padding-top: 4.3pt; padding-bottom: 4.3pt">January 1 and July 1, commencing January 1, 2026</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Record Dates:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">June 15 and December 15</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Optional Redemption</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">Make-whole call @ T+20 bps</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Provisions:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">Par call on or after June 1, 2030</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>CUSIP/ISIN Numbers:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">681936 BP4 / US681936BP48</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Use of Proceeds:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">The Issuer intends to use the proceeds of this offering for general corporate purposes, which may include repaying debt and future acquisition or investment opportunities and to pay certain fees and expenses related to this offering. Until the proceeds from a sale of securities by the Issuer are applied to their intended uses, they may be invested in short-term, investment grade, interest-bearing securities, certificates of deposit or indirect or guaranteed obligations of the United States.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Joint Book-Running Managers:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wells Fargo Securities, LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Credit Agricole Securities (USA) Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. Morgan Securities LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Citizens JMP Securities, LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Barclays Capital Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Huntington Securities, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KeyBanc Capital Markets Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M&amp;T Securities, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mizuho Securities USA LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Stanley &amp; Co. LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MUFG Securities Americas Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RBC Capital Markets, LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regions Securities LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scotia Capital (USA) Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Truist Securities, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt"><B>Co-Managers:</B></TD>
    <TD STYLE="padding-top: 4.3pt; padding-bottom: 4.3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BMO Capital Markets Corp.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BNP Paribas Securities Corp.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raymond James &amp; Associates, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SMBC Nikko Securities America, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stifel, Nicolaus &amp; Company, Inc.</P>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>*An explanation of the significance of ratings may be obtained
from the rating agencies. Generally, rating agencies base their ratings on such material and information, and such of their own
investigations, studies and assumptions, as they deem appropriate. The ratings of the notes should be evaluated independently from
similar ratings of other securities. A credit rating of a security is not a recommendation to buy, sell or hold securities and may
be subject to review, revision, suspension, reduction or withdrawal at any time by the assigning rating agency.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The issuer has filed a registration statement (including a preliminary
prospectus supplement and a prospectus) with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) for the offering to which
this communication relates. Before you invest, you should read the preliminary prospectus supplement and prospectus in that registration
statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You
may get these documents for free by visiting EDGAR on the SEC&rsquo;s website at <U>www.sec.gov</U>. Alternatively, the issuer, any underwriter
or any dealer participating in the offering will arrange to send you the prospectus supplement and prospectus if you request it by calling
Wells Fargo Securities, Inc. toll-free at 1-800-645-3751, BofA Securities, Inc. toll-free at 1-800-294-1322, Credit Agricole Securities
(USA) Inc. at 866-807-6030, or J.P. Morgan Securities LLC collect at 1-212-834-4533.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended,
trades in the secondary market generally are required to settle in one business day, unless the parties to such trade expressly agree
otherwise. Accordingly, purchasers who wish to trade the Notes prior to the first business day before their delivery will be required,
by virtue of the fact that the Notes initially will settle in seven business days (T+7), to specify alternative settlement arrangements
to prevent a failed settlement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Form of Certificate of the Chief Financial Officer
of the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">I, Robert O. Stephenson, Chief Financial Officer
of Omega Healthcare Investors, Inc., a Maryland corporation (the &ldquo;Company&rdquo;), hereby certify, on behalf of the Company and
its subsidiaries, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>I am knowledgeable with respect to the accounting records and internal accounting practices, policies, procedures and controls
of the Company and its subsidiaries and as the Chief Financial Officer of the Company have responsibility for financial and accounting
matters with respect to the Company and its subsidiaries, including, among other things: (i) preparing quarterly and annual financial
statements and related disclosures for the Company in conformity with generally accepted accounting principles in the United States and
(ii) maintaining adequate internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>I, or persons under my supervision, have reviewed the circled information on the attached copies of selected pages from the preliminary
prospectus dated June 10, 2025 (the &ldquo;Preliminary Prospectus&rdquo;), including pages from certain of the documents incorporated
by reference therein (the &ldquo;Circled Information&rdquo;), and believe such Circled Information, as of the date of the Preliminary
Prospectus and the date hereof, matches or is accurately derived from the applicable internal accounting or financial records of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">This certificate is being furnished to the Underwriters
to assist the Underwriters in conducting and documenting their investigation of the affairs of the Company in connection with the offering
and sale of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Capitalized terms used herein without definition
shall have the respective meanings ascribed to them in the underwriting agreement between the Company, the Subsidiary Guarantor referred
to therein and the Underwriters referred to therein dated as of June 10, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">IN WITNESS WHEREOF, the undersigned has hereunto
set his hands on the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OMEGA HEALTHCARE INVESTORS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">for itself and its subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-top: 6pt; border-bottom: Black 1pt solid; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-top: 6pt; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-top: 6pt; text-align: left; vertical-align: bottom">Name: Robert O. Stephenson</TD>
  <TD STYLE="padding-top: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-top: 6pt; text-align: left; vertical-align: top">Title: Chief Financial Officer</TD>
  <TD STYLE="padding-top: 6pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2517623d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Omega Healthcare Investors Announces Pricing of Its $600,000,000
Senior Notes Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 10, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Omega Healthcare Investors, Inc. (NYSE: OHI) (&ldquo;Omega&rdquo;)
today announced that it priced an underwritten public offering of $600,000,000 aggregate principal amount of 5.200% Senior Notes due 2030
(the &ldquo;2030 Notes&rdquo;). The settlement of this offering is expected to occur on June 20, 2025, subject to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Omega intends to use the net proceeds from the offering for general
corporate purposes, which may include, among other things, repayment of existing indebtedness and future acquisition or investment opportunities
in healthcare-related real estate properties and to pay certain fees and expenses related to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2030 Notes are guaranteed by Omega&rsquo;s subsidiary, OHI Healthcare
Properties Limited Partnership, and will be guaranteed by Omega&rsquo;s existing and future subsidiaries that guarantee unsecured indebtedness
for money borrowed of Omega in a principal amount at least equal to $100 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wells Fargo Securities, LLC, BofA Securities, Inc., Credit Agricole
Securities (USA) Inc. and J.P. Morgan Securities LLC are acting as active joint book-running managers for the offering of the 2030 Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2030 Notes will mature on July 1, 2030, have an issue price to
the public of 99.118% and feature a fixed-rate coupon of 5.200% per annum, payable semiannually on January 1 and July 1 of each year,
beginning January 1, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering is being conducted by means of a prospectus supplement
filed as part of a shelf registration statement on Form S-3 (Registration No. 333-282376) previously filed with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;). A copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering
of the Notes can be obtained from: Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, Minneapolis, MN 55402, Attention: WFS
Customer Service, or by email at&nbsp;<U>wfscustomerservice@wellsfargo.com</U>, or by calling (800) 645-3751; BofA Securities, Inc.,
NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at <U>dg.prospectus_requests@bofa.com</U>;
Credit Agricole Securities (USA) Inc., 1301 Avenue of the Americas, 8<SUP>th</SUP> Floor, New York, New York 10019, Attention: Debt Capital
Markets, or by email at <U>DCMNewYork@ca-cib.com</U>, or by calling +1 (866) 807-6030; J.P. Morgan Securities LLC, 383 Madison Ave.,
New York, NY 10179, Attention: Investment Grade Syndicate Desk, or by calling (212) 834 4533. Potential investors should read the prospectus
supplement and accompanying prospectus, the registration statement and the other documents that Omega has filed with the SEC in connection
with the offering of the Notes. A copy of the prospectus supplement and accompanying prospectus may also be obtained without charge by
visiting the SEC&rsquo;s website at&nbsp;www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation
or sale would be unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Omega is a real estate investment trust (&ldquo;REIT&rdquo;) that invests
in the long-term healthcare industry, primarily in skilled nursing (&ldquo;SNFs&rdquo;) and assisted living facilities (&ldquo;ALFs&rdquo;).
Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets
span all regions within the United States, as well as in the United Kingdom. More information on Omega is available at&nbsp;www.omegahealthcare.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Forward-Looking Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release includes forward-looking statements within the
meaning of the federal securities laws. All statements regarding Omega&rsquo;s or its tenants&rsquo;, operators&rsquo;, borrowers&rsquo;
or managers&rsquo; expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend
plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics,
capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities,
expected lease income, continued qualification as a REIT, plans and objectives of management for future operations and statements that
include words such as &ldquo;anticipate,&rdquo; &ldquo;if,&rdquo; &ldquo;believe,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; and other similar expressions are
forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega's expectations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Omega&rsquo;s actual results may differ materially from those reflected
in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the
business operations of the operators of Omega&rsquo;s properties, including those relating to reimbursement by third-party payors, regulatory
matters, occupancy levels and quality of care, including the management of infectious diseases; (ii) the timing of our operators&rsquo;
recovery from staffing shortages, increased costs and decreased occupancy resulting from inflation and the long-term impacts of the Novel
coronavirus (&ldquo;COVID-19&rdquo;) pandemic and the sufficiency of previous government support and current reimbursement rates to offset
such costs and the conditions related thereto; (iii) additional regulatory and other changes in the healthcare sector, including potential
changes to Medicaid or Medicare reimbursements, state regulatory initiatives or minimum staffing requirements for skilled nursing facilities
(&ldquo;SNFs&rdquo;) that may further exacerbate labor and occupancy challenges for Omega&rsquo;s operators; (iv) the ability of any of
Omega&rsquo;s operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega&rsquo;s mortgages and impede the
ability of Omega to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the
debtor&rsquo;s obligations, and other costs and uncertainties associated with operator bankruptcies; (v) changes in tax laws and regulations
affecting real estate investment trusts (&ldquo;REITs&rdquo;), including as the result of any policy changes driven by the current focus
on capital providers to the healthcare industry; (vi) Omega&rsquo;s ability to re-lease, otherwise transition or sell underperforming
assets or assets held for sale on a timely basis and on terms that allow Omega to realize the carrying value of these assets or to redeploy
the proceeds therefrom on favorable terms, including due to the potential impact of changes in the SNF and assisted living facility (&ldquo;ALF&rdquo;)
markets or local real estate conditions; (vii) the availability and cost of capital to Omega; (viii) changes in Omega&rsquo;s credit ratings
and the ratings of its debt securities; (ix) competition in the financing of healthcare facilities; (x) competition in the long-term healthcare
industry and shifts in the perception of various types of long-term care facilities, including SNFs and ALFs; (xi) changes in the financial
position of Omega&rsquo;s operators; (xii) the effect of economic, regulatory and market conditions generally, and particularly in the
healthcare industry and in jurisdictions where we conduct business, including the U.K.; (xiii) changes in interest rates and the impacts
of inflation and changes in global tariffs; (xiv) the timing, amount and yield of any additional investments; (xv) Omega&rsquo;s ability
to maintain its status as a REIT; (xvi) the effect of other factors affecting our business or the businesses of Omega&rsquo;s operators
that are beyond Omega&rsquo;s or operators&rsquo; control, including natural disasters, public health crises or pandemics, cyber threats
and governmental action, particularly in the healthcare industry, and (xvii) other factors identified in Omega&rsquo;s filings with the
Securities and Exchange Commission. Statements regarding future events and developments and Omega&rsquo;s future performance, as well
as management&rsquo;s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>We caution you that the foregoing list of important factors may
not contain all the material factors that are important to you. Accordingly, readers should not place undue reliance on those statements.
All forward-looking statements are based upon information available to us on the date of this release. We undertake no obligation to publicly
update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required
by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FOR FURTHER INFORMATION, CONTACT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Andrew Dorsey, VP, Corporate Strategy &amp; Investor
Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">David Griffin, Director, Corporate Strategy &amp;
Investor Relations at (410) 427-1705</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ohi-20250610.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaD6bOdzZR+OYkxtmB3bekKHykrWqASDi6hmloWoT0F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ohi="http://omegahealthcare.com/20250610" elementFormDefault="qualified" targetNamespace="http://omegahealthcare.com/20250610">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://omegahealthcare.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ohi-20250610_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ohi-20250610_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ohi-20250610_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ohi-20250610_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://omegahealthcare.com/role/Cover" xlink:href="ohi-20250610.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://omegahealthcare.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OMEGA HEALTHCARE INVESTORS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000888491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3041398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">303 International Circle<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hunt Valley<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">427-1700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.10 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OHI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2517623d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://omegahealthcare.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ohi-20250610.xsd</File>
    <File>ohi-20250610_lab.xml</File>
    <File>ohi-20250610_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2517623d1_8k.htm">tm2517623d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2517623d1_8k.htm": {
   "nsprefix": "ohi",
   "nsuri": "http://omegahealthcare.com/20250610",
   "dts": {
    "schema": {
     "local": [
      "ohi-20250610.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ohi-20250610_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ohi-20250610_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2517623d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://omegahealthcare.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2517623d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2517623d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://omegahealthcare.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-25-058593-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-058593-xbrl.zip
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MR)QFPBP/@@7 E,E (4-*APJAEY[7=PE8IAYB!)MCRMP28#?9I*"I"8@$JS&
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M[G&K*(C>[W)FDE!J45/L&(L%ITF49 E;_RI//D6";:VRB5P! 1O4-+050:
MVC(Y. B15CJ&X$X0!2&1'9&_!*@2"XG;AP?K;-\E=@5%OV$-!ZP, I)>>R8L
M,F <U2)0$8+R&+_8S--T2\2;X+&$>$((- ^ U-*'B!-DLA>J(M G6PL2;>7\
MN#^9KI9)1FTGEVV)LSD),%?-2$9Y$&P IDP6\C+$']#)].^K?R =Y;C[;_A2
M8)4[=K'?K#@%LD]95:X@Z+"H.;!(@D !]F72<,-1*46%UD=VJH992W.,<E<
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M=^WIZID-_M2]P'JWAX/.[:YF<$T^QQ^ZMML=[=8^]*Y]>ZST#3X35@44Q.&
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M^W<GA5Y0E>AEE.J\SCAQB<P ]#7NV$Q+SCW,ZXI3TL3*\*SL72GCDF6? BF
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MK ,G$ /,D=>AHQLG1VDZ3/GU;/=F'TQ5M*[2$<S6E9LU)J*'2P:K>[H\WBE
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MTZT#_INBX+L2\=?7MU>JM*G+I2O4WZ4"R(]=?GAM"V.@]J_I=$' 0E(I,$)
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MT_NDX,9;#F]3?_S'3P*3-!P\VK_#3$O_G\#0R8>?WHEI!0.,I/;[I2NW8P\
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MP9,F<(*TZ,)^>M)QJ]2MT053VLMZ%,'NZMXTID&CP3V[I:NE>?*V*+.[^Z*
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M(XNGI/89%+\ECB[G 1*C%VW.&3F-^EV9YE+R/%@5OK\$RMH^C/:&2D,^]L,
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MVC@>3/6+>N.B!N5]3$"L65Z#6)K8]#.TTTTU9G$5)VE*8BO'@-I5$E^'QN/
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M+,I@QRAVI0;;V;4CX8%W#%:N,!/>2#<A!^EU#&=1DLQ8G</[LV@>EUVZ%Z.
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M!456A= K.3"1G!O72Z&"[_'/*"*$ZTXKGA]I$GW);O5VX^,-[G%BQM(A%GJ
M<Y]:5-3CP;2B'SX^+6X$M0?::C:1)X4VM]?S5>Z2\/-.MIWFQ?LB12X\/CX6
M\2H/EXQE$9"0^\++2"^24:,ZQ,IFI\H@T>C'?%=#7$HWY(E4;ASBP;"M7B)1
M6F:&T@_"P(DM*(KL@5%5Z:$?@-L7<3J6<Z>CYG0LYT['E]BI#:6V1EWN16-I
M<:7CJTBMT%.EVT0#XL+NSLCF&%ECJ5([8WP(^U>/J!-T%!>CBM&.#).SJ#9
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MI\<^&?BB,#<JON^:EA%LM.S:#.JL@E':UZ#AWEC?OKDIUD=.D9?DEQG1$>W
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MHLIJTR.^J=Z>?Z5]<MFYOOKP/U!+ P04    " "]B\M:Q2E&-JD0   ,-P
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M .T\/%)5,BTY'0-0IDKFE*PYR(VC/%T2>,UF/I\#''1&C,-!?[;P(]U$92E
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M              "  0    !O:&DM,C R-3 V,3 N>'-D4$L! A0#%     @
MO8O+6B0NS8S\"@  ?X8  !0              ( !60,  &]H:2TR,#(U,#8Q
M,%]L86(N>&UL4$L! A0#%     @ O8O+6AU8L(M;!P  X5<  !0
M     ( !APX  &]H:2TR,#(U,#8Q,%]P<F4N>&UL4$L! A0#%     @ O8O+
M6I_@:)DK%   A6P  !(              ( !%!8  '1M,C4Q-S8R,V0Q7SAK
M+FAT;5!+ 0(4 Q0    ( +V+RUH1O\X]DI4  /K' P 5              "
M 6\J  !T;3(U,3<V,C-D,5]E>#$M,2YH=&U02P$"% ,4    " "]B\M:Q2E&
M-JD0   ,-P  %@              @ $TP   =&TR-3$W-C(S9#%?97@Y.2TQ
:+FAT;5!+!08     !@ & (D!   1T0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tm2517623d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ohi-20250610.xsd" xlink:type="simple"/>
    <context id="AsOf2025-06-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000888491</identifier>
        </entity>
        <period>
            <startDate>2025-06-10</startDate>
            <endDate>2025-06-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-06-10" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-06-10" id="Fact000004">0000888491</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-06-10" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-06-10" id="Fact000011">2025-06-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-06-10" id="Fact000012">OMEGA HEALTHCARE INVESTORS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-06-10" id="Fact000013">MD</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-06-10" id="Fact000014">1-11316</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-06-10" id="Fact000015">38-3041398</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-06-10" id="Fact000016">303 International Circle</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-06-10" id="Fact000017">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-06-10" id="Fact000018">Hunt Valley</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-06-10" id="Fact000019">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-06-10" id="Fact000020">21030</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-06-10" id="Fact000021">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-06-10" id="Fact000022">427-1700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-06-10" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-06-10" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-06-10" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-06-10" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-06-10" id="Fact000027">Common Stock, $.10 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-06-10" id="Fact000028">OHI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-06-10" id="Fact000029">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-06-10" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
